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we have not sufficiently desired. 
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SUMMARY 
 
Extracellular vesicles (EVs) are membrane-covered cell fragments released 
by most cell types, in different physiological and pathophysiological 
conditions. 
Although a definitive categorization has yet to be achieved, EVs can be 
classified in three classes: apoptotic bodies (ABs), 
microvesicles/microparticles (MVs/MPs) and exosomes (EXOs). Due to 
numerous similarities that exist among them the separation is still a 
challenge so a standardized approach to their isolation and characterization 
is required. 
In the first part of this thesis, we focused on proper separation and 
characterization of subpopulations of EVs. 
First of all we compared a differential centrifugation-based protocol used to 
isolate ABs and MVs and another protocol used to isolate EXOs after 
removal of ABs and MVs. EVs from supernatant of three cell lines were 
characterized focusing on their morphology, RNA profile and surface 
marker expression. We demonstrated that pellets showed highly different 
distribution of size, shape and electron density with typical AB, MV and 
EXO characteristics. Distinct vesicles fractions had clearly different RNA 
profiles. rRNA was primary detectable in ABs and smaller RNAs without 
prominent rRNA profiles in EXOs. By contrast, MVs contained little or no 
RNA except for those collected from TF-1 cells. Moreover, we showed that 
markers considered typical of EXOs (CD9, CD63 and CD81) were present 
in all EV types when vesicles were analyzed by flow cytometry using anti-
CD63-coated beads.  
To further investigate EV subpopulations, we demonstrated that two 
populations of exosome-like vesicles could be identified with or without 
using 0.22 µm filter. In particular, just one pellet was collected using filter 
(“EXOs w/o filter”) whereas two different pellets were collected without 
filter: “additional pellet”, at the bottom of the tube and “EXOs w filter”, 
attached to the tube. As well as for ABs, MVs and EXOs, they showed 
different RNA profiles with mostly short RNAs in “EXO w filter”, more 
evident rRNA peaks in “EXOs w/o filter” and prominent RNA peaks in the 
“additional pellet”.  Moreover, loading “EXO w filter” and “additional 
pellet” on sucrose gradient, RNA profile analysis showed that RNAs in the 
two pellets have a different distribution. In “EXO w filter”, small RNA was 
found in lower fractions whereas “additional pellet” showed both rRNA-
positive fractions (in upper fractions) and rRNA-negative fractions (in lower 
fractions). Our results demonstrated that the differences shown in EXO 
studies could be due not only to a different EXO origin, but also to the 
different filter used. 
Further investigation demonstrated that EV nomenclature is still a problem; 
authors often investigated the same type of vesicles, but called them in 
different ways. By loading ABs, MVs, EXOs as well as “EXO w filter” and 
“additional pellet” on sucrose gradient and looking at RNA profiles, we 
demonstrated that MV pellet was composed by both rRNA-positive vesicles 
(in upper fractions) and RNA-negative vesicles (in lower fractions) similar 
to what observed in “additional pellet”. Fractions obtained from EXO pellet 
were composed only by rRNA-negative vesicles as observed in fractions 
from “EXO w filter”.  
After the development of EV isolation method, able to reduce the 
contamination between different EV types, we applied our technical 
knowledge to investigate EVs in a specific biological process: ribosomal 
stress, a condition caused by aberrant ribosome biogenesis. Defects of 
ribosome biogenesis lead to a number of ribosomal diseases. Diamond 
Blackfan Anemia (DBA) is the first human disorder discovered in this 
group. Abnormal ribosome biogenesis induces apoptosis in erythroid 
progenitors so DBA research is limited by the unavailability of the disease 
cell target. Analysis of EVs shed from erythroid progenitors is useful to 
overcome this limitation.  
First we investigated EV miRNA composition in CD34+ cells after induction 
of ribosomal stress due to silencing of RPS19 (DBA cell model) and then 
we evaluated EVs in blood from patients with DBA. miRNAs that were 
included in MVs/EXOs released during ribosomal stress (CD34+C) were 
compared with those identified in their scramble control (CD34+S). 
Specifically, in MVs C versus MVs S, three miRNA were up-regulated 
(miR-412, miR-1281, miR-1273f) and eight were down-regulated (miR-
153, miR-1248, miR-526b-5p, miR452-5p, miR-105-5p, miR-374a-5p, 
miR-148a-3p and miR-588). Comparing miRNAs changed in EXOs C 
versus EXOs S, just one miRNA showed to be up-regulated (miR-643), 
whereas four miRNAs were down- regulated (miR-654-3p, miR-1276, miR-
539-5p and miR-188-3p). Interestingly, two of these miRNAs are involved 
in cell death i.e. miR-412 and miR-153. miRNA signature in MVs and 
EXOs released in ribosomal stress has been identified for the first time. 
The finding of abnormalities in vesicles shed from cells representing a 
model for DBA prompted us to explore the diagnostic potential of erythroid 
vesicles in patients with DBA. MPs were collected from blood of patients 
with DBA, patients showing a non-DBA haematological disease and healthy 
controls. Vesicle markers were studied by flow cytometry: CD34, CD71 
CD235a (Glycophorin A) and phosphatidylserine (PS). The MP number in 
specific gates has been calculated. Interestingly, we found that the 
CD34+/CD71low population was absent in anemic patients with DBA, but 
was well represented in healthy controls and in patients affected by a non-
DBA condition. The receiver operating curve (ROC) analysis showed that 
MP CD34+/CD71low evaluation had a good diagnostic value for DBA 
diagnosis. Other MP populations have been identified demonstrating that 
flow cytometry is able to analyse MP shed from hematopoietic cells at 
different developmental stage. 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
1. Introduction 1 
 
1.1 Extracellular vesicles (EVs) 2 
1.1.1 Apoptotic bodies (ABs) 3 
1.1.2 Microvesicles (MVs) 5 
1.1.3 Exosomes (EXOs) 7 
 
1.2 Molecular composition of extracellular vesicles 9 
 
1.3 Isolation and characterization methods 10 
 
1.4 Extracellular vesicles: medical implications and therapeutic/diagnostic 
potential 13 
 
1.5 Extracellular vesicles from blood samples 16 
1.5.1 Pre-analytical challenges 16 
1.5.2 Methods of EV analysis in blood 18 
 
1.6 Erythropoiesis and erythroid progenitor markers 19 
1.6.1 Extracellular vesicles from reticulocytes 22 
 
1.7 Extracellular vesicles released during cellular stress – p53 involvement 24 
 
1.8 Ribosomal stress: cell proliferation inhibition through p53-dependent and -
independent mechanisms 27 
 
1.9 Diamond Blackfan Anemia (DBA), a human disease due to ribosomal  
stress 29 
1.9.1 Clinical features and molecular basis 29 
1.9.2 Global gene expression in p53 null-cell models of DBA suggests 
activation of p53-independent pathways (Aspesi et al, submitted to Gene) 31 
 
2. Overview of the objectives 57 
 
3. Results and discussion 59 
 
3.1 Isolation and characterization of EVs: RNA profile analysis distinguishes 
EV subpopulations 60 
3.1.1 Centrifugation based protocols to separate ABs, MVs and EXOs  
(Crescitelli et al, 2013) 60 
3.1.2 Effect of filtration on the purity of exosome fraction: identification of 
two types of exosome-like vesicles 73 
· Aim of the project 73 
· Experimental plan and methods 73 
· Results and discussion 75 
3.1.3 RNA characterization in EV subpopulations: RNA profile  
comparison between exosomes-like vesicles and ABs, MVs and EXOs 80 
· Aim of the project 80 
· Experimental plan and methods 80 
· Results and discussion 82 
 
3.2 Study of extracellular vesicles in ribosomal stress 87 
3.2.1 MicroRNA signature in MVs/EXOs shed from CD34+ cells down- 
regulated for RPS19 (DBA cell model) 87 
· Aim of the project 88 
· Experimental plan and methods 88 
· Results and discussion 90 
3.2.2 Diagnostic potential of extracellular vesicles – characterization 
 and quantification of microparticles in patients with Diamond Blackfan 
Anemia (DBA)                                                                                                 96 
· Aim of the project 96 
· Experimental plan and methods 97 
· Results and discussion 100 
 
4. Conclusions and future perspectives 118 
 
References 126 
 
Acknowledgments 145 
	   
 
 
 
 
 
 
 
 
 	  
1. Introduction 	  
 
1.	  Introduction	  
	   2	  
1.1 Extracellular vesicles (EVs) 
 
Extracellular vesicles (EVs) are membrane-covered cell fragments released 
by most cell types, in different physiological and pathophysiological 
conditions (Théry C., 2009), (Mathivanan S J. H., 2010), (Ratajczak J., 
2006), (Cocucci E, 2009), (Johnstone RM, 2006).  
They can be detected in body fluids including blood, plasma, urine, saliva, 
amniotic fluid, milk, pleura ascites (Simpson RJ, 2009), (Lässer C A. V., 
2011), and contain proteins, lipids and RNA that are representative of host 
cell (Valadi H, 2007), (Théry C Z. L., 2002), (Mathivanan S L. J., 2010). It 
is becoming increasingly clear that they have specialized functions and play 
a key role in intracellular signalling, waste management and coagulation. 
Consequently, there is a growing interest in the clinical application of EVs. 
Vesicles can potentially be used for therapy, prognosis and as disease 
biomarker (van der Pol E B. A., 2012). 
The discovery of EV dates back to 1940, thanks to preliminary studies 
performed with the aim to study the “biological significance of 
thromboplastic protein of blood” (Chargaff E, 1946). More than twenty 
years later, this subcellular fraction was identified by electron microscopy 
and was shown to consist of small vesicles, originating from platelets and 
termed “platelet dust” (Wolf P., 1967). Ten years later, numerous 
microvesicles were detected in foetal calf serum (Dalton AJ., 1975). From 
this preliminary studies, dozen of different names have been used for 
extracellular vesicles based on their specific function: calcifying matrix 
vesicles that initiate bone formation (Anderson HC., 1969), tolerosomes that 
induce immunological tolerance, or their cell origin: dexosomes (dendridic 
cell-derived exosomes) (Le Pecq JB., 2005), prostasomes (prostate-derived 
exosomes) (Stegmayr B, 1982), matrix vesicles (vesicles in bone, cartilage 
and atherosclerotic plaques) (Tanimura A, 1983), synaptic vesicles (vesicles 
from neurons) (Fischer von Mollard G, 1990). Though a definitive 
categorization is yet to be achieved (Simpson RJ., 2012), EVs can be 
classified in three classes based on their size and presumed biogenetic 
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pathways: apoptotic bodies (ABs), microvesicles (MVs) and exosomes 
(EXOs) (Kalra H, 2012) (Fig.1). 
 
 
 
Fig.1: Schematic representation of extracellular vesicles (EVs). Principal 
populations are shown: apoptotic bodies (ABs), microvesicles (MVs) and 
exosomes (EXOs). Modified from György B et al, 2011. 
 
 
 
1.1.1 Apoptotic bodies (ABs) 
 
In 1972, for the first time, the term “apoptotic body” has been used (Kerr 
JF, 1972), but Horviz R. et al conducted the seminal work in apoptosis 
research studying cell development in Caenorhabditis elegans (Sulston JE, 
1977) (Fixsen W, 1985).  
These particles have a size between 1-5 µm, similar to the size range of 
platelets (Hristov M, 2004), a density between 1.16 to 1.29 g/ml, partially 
overlapping with exosome density and a morphology that is heterogeneous 
when compared with other vesicles visualized by TEM (van der Pol E B. A., 
2012). They are released as blebs from cells undergoing apoptosis. A cell 
dying by apoptosis goes through several stages: they start with condensation 
of the nuclear chromatin, followed by membrane blebbing and progress to 
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disintegration of the cellular content into membrane vesicles termed 
apoptotic bodies. The clearance of apoptotic bodies by macrophages is 
mediated by specific interactions between recognition receptors on the 
phagocytes and the specific changes (such as oxidation of surface 
molecules) in the composition of the apoptotic cell membrane. These 
changes create binding sites for Thrombospondin (Tsp) or the complement 
protein C3b (Akers JC, 2013). (Fig.2) 
 
 
Fig.2: Formation of apoptotic bodies during apoptosis. Modified from Akers JC et 
al, 2013. 
 
Apoptotic cells release two different types of apoptotic vesicles: the first 
one originates from the plasma membrane and contains DNA and hystones, 
whereas the other originates from endoplasmic reticulum and does not 
contain DNA or hystones, but exposes immature glycoepitopes (Bilyy RO, 
2012). For studies focused on cells undergoing apoptosis, generally, authors 
look at the phosphatidylserine expression and DNA fragmentation (Beyer C, 
2010). ABs are involved in horizontal transfer of DNA (Holmgren L, 1999) 
including oncogenes (Bergsmedh A, 2001) and presentation of T cell 
epitopes (Bellone M, 1997). 
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1.1.2 Microvesicles (MVs) 
 
They were described for the first time by Chargaff and West in 1946 
(Chargaff E, 1946). Twenty years later, Wolf P. isolated a fraction 
composed by lipid-rich particles obtained by ultracentrifugation from 
plasma and called them “platelet dust” (Wolf P., 1967). 
MVs have a size between 100-1000 nm (Théry C O. M., 2009) overlapping 
that of bacteria, but there is no consensus on the lower cut-off (Yuana Y, 
2011). They are surrounded by phospholipid bilayer and are shed directly 
from budding of plasma membrane (György B S. T., 2011). They are 
released during cell stress conditions (van der Pol E B. A., 2012) after 
activation of cell surface receptors or during apoptosis following 
intracellular Ca2+ increase (Baroni M, 2007), (Kahner BN, 2008). These 
vesicles are involved in procoagulant function (Leroyer AS, 2008), in the 
pathogenesis of rheumatoid arthritis (Boilard E, 2010), tumour proinvasive 
activity (Giusti I, 2008), neoplastic transformation (Antonyak MA, 2011), 
foetus-mother communication (Pap E, 2008). They are generally 
characterized by phosphatidylserine but some observations suggest the 
existence of MVs that are negative for this marker (Connor DE, 2010).  
They are isolated using centrifugation-based protocols (Yuana Y, 2011) 
using a centrifugation force of 10,000-20,000 g (Théry C O. M., 2009) or 
capture-based assays (Sellam J, 2009) followed by flow cytometry (György 
B M. K., 2011).  
Few proteins seem to be ubiquitously expressed; an example is β1 integrin 
(Dolo V, 1998). MV composition depends on cell of origin. MVs from 
tumours express metalloproteinases and other proteolytic enzyme (Gutwein 
P, 2003), (Gasser O, 2003), whereas MVs from platelets express integrins, 
glycoproteins GPIb, GPIIb-IIIa and P selectin (Del Conde I, 2005), 
(Cocucci E, 2009). MVs are able to interact with cells that they recognize 
specifically and transfer receptors, ligands, mRNAs and miRNAs 
contributing to epigenetic ad proteomic properties of target cells (Fig.3) 
(Hunter MP, 2008), (György B M. K., 2011). 
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Fig. 3: MV-mediated intercellular communication. Components of donor cells are 
incorporated into MVs that contain proteins, RNAs and DNA. MVs can be taken 
up by recipient cells through endocytosis and release their contents after fusing 
with the endosomal membrane or the plasma membrane. Modified from van der 
Vos KE et al, 2011. 
 
 
It has been demonstrated that they induce change in the maturation and 
differentiation of target cells. For example, MVs from neutrophils can 
impair the maturation of dendritic cells (Eken C, 2008).  
They have been through studied in coagulation. Upon exposure to collagen, 
platelets release MVs coated with tissue factor which binds with its surface 
ligand (for example P-selectin1) on macrophages (Polgar J, 2005), 
neutrophils (Pluskota E, 2008) and other platelets.  
An increased amount of MVs has been observed in plasma from patients 
with anti-phospholipid syndrome (Asherson’s syndrome) (Ardoin SP, 2007) 
as well as in inflammatory conditions (Distler JH, 2005).  
They have roles in tumours progression and contribute to angiogenic effect 
through horizontal transfer of mRNAs and miRNAs (Skog J, 2008).  
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Because of these properties EVs are considered as potentially innovative 
targets for therapy. 
 
1.1.3 Exosomes (EXOs) 
 
The term “exosome” was first used in 1981 for vesicles with nucleotidase 
activity that were shed from neoplastic cell lines (Trams EG, 1981). In 1983 
Stahl and Johnstone (Harding C, 1983), (Pan BT T. K., 1985) described 
small vesicles containing transferrin receptor that were released from 
reticulocytes. 
EXOs have a diameter between 50-100 nm and a density that ranges 
between 1.13 and 1.19 g/ml. They show a phospholipid bilayer structure 
with a size overlapping that of viruses. They are found in many fluids 
(urines, blood, ascites, cerebrospinal fluid) (Caby MP, 2005), (Pisitkun T, 
2004), (Keller S, 2006), (Vella LJ, 2008). 
Differential centrifugations followed by sucrose gradient 
ultracentrifugations are typically used for EXO isolation (Théry C A. S., 
2006). Transmission electron microscopy (TEM), western blot and mass 
spectroscopy are used for their characterization. Using TEM, the 
morphology of exosomes has been described as cup-shaped (Johnstone RM 
A. M., 1987). However, more recent studies have shown that the cup-shaped 
morphology was an experimental artefact caused by the procedures used to 
prepare samples (Conde-Vancells J, 2008). 
The exosome formation process starts with the invagination of plasma 
membrane (endocytosis) (Huotari J, 2011). This process can be clathrin-
mediated (classical pathway) or clathrin independent, a less studied process 
compared to the first one (Le Roy C, 2005). Within the cell, endocytic 
vesicles fuse with early endosomes that mature into late endosomes and 
then in multivesicular bodies (MVBs). Two types of MVBs are recognized; 
one is formed in the degradative pathway (i.e. MVBs that fuse with 
lysosomes) and the other in the exocytosis pathway (i.e. MVBs that fuse 
with plasma membrane) (Mathivanan S S. R., 2009). Exosomes are formed 
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by endocytosis of early endosome membrane (Roizin L, 1967). MVB 
generation and exosome secretion depend on the action of the ESCRT 
complex, an endosomal complex that is required for transport (Wollert T, 
2010) (Fig. 4). 
 
 
 
Fig. 4: Schematic description of exosome (EXOs) release. EXOs are represented 
by small vesicles of different sizes that are formed by budding from early 
endosomes or MVBs and they are released by fusion with the plasma membrane. 
Other MVBs fuse with lysosomes. Modified from Raposo G et al, 2013. 
 
 
To date, the most studied and characterized EXOs are those released from 
immune and tumour cells. They are involved in antigen presentation (Théry 
C., 2009), (Raposo G N. H., 1996), immunostimulation, tumour growth, 
metastasis and angiogenesis (van der Pol E B. A., 2012). Thus they can 
protect tumour cells inhibiting antitumor drug accumulation. They can 
contribute to multidrug resistance (Ciravolo V, 2012).  
They exert their functions in different ways: direct exosome-cell contact, 
vesicle endocytosis and exosome-cell fusion (Théry C., 2009). As well as 
microvesicles, they can transfer mRNAs and miRNAs (Valadi H, 2007), but 
also oncogenic receptors (Al-Nedawi K M. B., 2008) and HIV particles 
(Izquierdo-Useros N, 2009). By transporting ligands and receptors, they can 
1.	  Introduction	  
	   9	  
drive cell growth and development and thus also modulate the immune 
system (van der Pol E B. A., 2012). For example, it has been demonstrated 
that activated T cells and peripheral blood mononuclear cells release EXOs 
expressing Fas Ligand suggesting that they have a role in cell death during 
immune regulation (Martínez-Lorenzo MJ, 2004). 
Structurally, they are characterized by phosphatidylserine exposure (Chaput 
N, 2011) and high levels of cholesterol, sphingomyelin, ceramide and lipid 
rafts (Wubbolts R, 2003), (Simons M, 2009), (Mathivanan S J. H., 2010), 
(Théry C A. S., 2006). Typical EXO markers are tetraspanins such as CD63, 
CD81, CD9 and proteins like LAMP1 and TGS101 (Mathivanan S J. H., 
2010), (Dignat-George F, 2011) Alix complex, heat shock proteins as well 
as proteins involved in membrane transport and fusion, like Rab, GTPase, 
annexin and flottilin (Théry C Z. L., 2002), (Beyer C, 2010), (Bobrie A C. 
M., 2011), (Record M, 2011).  
 
 
1.2 Molecular composition of extracellular vesicles 
 
As mentioned in chapter 1.1, the protein composition reflects the origin of 
the parental cells (Pap E, 2008). EXOs from different cell lines contain 
endosome-associated proteins such as Rab GTPase, SNARE, Annexin, 
flotillin. Some of them are involved in multivesicular endosomes 
biogenesis, such as Alix and Tsg101 (van Niel G, 2006). EVs are enriched 
in membrane proteins because of their plasma membrane or endosome 
origin. Tetraspanins are among the most common membrane proteins in all 
EVs, e.g. CD63, CD81, CD82, CD53 and CD37. They were firstly 
identified in EXOs from B cells (Escola JM, 1998). EVs are also enriched in 
proteins associated with lipids raft (such as flotillin) (Théry C R. A.-C., 
1999).  
EXOs expose different saturated and monosaturated fatty acids as well as 
cholesterol and sphingomyelin. Little is known about specific proteins and 
lipid composition of MVs (Raposo G S. W., 2013). 
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In 2007, Valadi et al demonstrated that EVs included both mRNAs and 
miRNAs. mRNAs from EVs can be translated in protein when inserted in 
target cells. 1300 mRNAs were found in EXOs from mouse mast cell line, 
human mast cell line and BMMC (Bone Marrow-derived Mast Cells) 
(Valadi H, 2007). Extracellular RNA has been found not only in EXOs but 
also in MVs (Grange C, 2011) and ABs (Zernecke A, 2009). The mRNAs or 
miRNAs reflect the originating cell profile (Skog J, 2008), (Ratajczak J., 
2006). Beyond mRNAs and miRNAs many authors demonstrated that EVs 
contain other small non coding RNAs such as tRNA fragments, Y RNA, 
small interfering RNA (Bellingham SA, 2012), (Nolte-'t Hoen EN, 2012) as 
well as fragments of 28S and 18S rRNA subunits (Jenjaroenpun P, 2013).  
The complete protein, lipid and RNA composition of EVs is listed in two 
online databases: ExoCarta (www.exocarta.org) and EVPedia 
(www.evpedia.info/).  
 
 
1.3 Isolation and characterization methods  
 
Extracellular vesicle studies are hampered by lack of a standardized 
protocol that distinguishes different vesicle types (Onodera T, 2010). 
Numerous similarities exist among the different EVs; this makes the 
separation of different subsets a challenge (György B S. T., 2011). 
The widely accepted protocol for EXO isolation includes ultracentrifugation 
followed by sucrose density gradient or cushions (Théry C A. S., 2006). 
However, a differential centrifugation protocol based on different 
centrifugations with increased force, is considered the “gold standard” 
system (Stephen J. Gould, 2013) and useful to separate subpopulations of 
extracellular vesicles at different steps. The use of a filtration step is 
debated. There is not a general agreement on the optimal isolation protocol 
for MVs or ABs.  
In general, the isolation procedure includes a first centrifugation step (200-
1,500 × g) to eliminate cells and cellular debris followed by a stronger 
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centrifugation (10,000-20,000 × g) to eliminate vesicles with a bigger size 
(100-800 nm generally called MVs). A higher speed centrifugation (100,000 
– 200,000 × g) is able to pellet EXOs (Mathivanan S J. H., 2010), (Théry C 
Z. L., 2002), (Théry C A. S., 2006).  
To better purify pellets, EVs can be loaded on sucrose gradient or cushions 
(Théry C A. S., 2006). Other systems include immunoaffinity isolation 
(employing magnetic beads conjugated with antibodies directed against EV 
protein markers) (Clayton A C. J., 2001), nanomembrane ultrafiltration 
concentrator (Cheruvanky A, 2007). 
Several companies developed kits to isolate EXOs or to distinguish different 
EV subpopulations. The most used kits are ExoQuickTM from System 
Biosciences and “Total Exosome Isolation” from Invitrogen. Moreover 
Bioo Scientific Company developed the ExoMirTM Plus kit that uses filters 
with pores of different diameters and allows to directly isolate RNA from 
cells, ABs, MVs and EXOs, without centrifugation steps. 
However, it is important to state that, since vesicles are heterogeneous, there 
is no system able to accurately separate a specific type. The isolation 
efficiency depends on the shape and viscosity of solution, as well as on 
temperature, centrifugation time and the rotor type used for the 
centrifugation (van der Pol E B. A., 2012). Furthermore, isolation methods 
are based on size, sedimentation, density, and surface molecules, but there is 
no consensus about these specific characteristics for each subpopulation of 
extracellular vesicles. For example MV density is unknown, and there is no 
agreement on specific EXO markers that are able to distinguish EXOs from 
MVs (Théry C., 2009).  
For these reasons there is a need to develop a standardized method to 
distinguish EV types (Tauro BJ, 2012), (Yamada T, 2012), (Taylor DD Z. 
W.-T., 2011).  
Because of all these limits, a combination of different methods has been 
suggested. Due to their small size, it is not possible to use optical methods 
to visualize EXOs as well as MVs and ABs. They can only be directly 
visualized by electron microscopy (TEM). To date, TEM is considered the 
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gold standard for vesicles size determination, but the procedures used to 
obtain the pellet (centrifugation, dehydration, fixation) could alter EV 
morphology (György B S. T., 2011). Electron microscopy is the only 
method that shows the presence of different subpopulations of extracellular 
vesicles (Lässer C E. M., 2012). Thanks to other techniques such as Cryo-
EM (Tatischeff I, 2012), scanning electron microscopy (Sokolova V, 2011) 
and atomic force microscopy (György B M. K., 2011), nowadays 
researchers consider the cup-shaped EXO morphology, a TEM artefact due 
to fixation process (Théry C A. S., 2006). A very innovative method is 
Raman tweezers microspectroscopy (RTM) that provides an EXO global 
composition without using any exogenous label (Tatischeff I, 2012).  
Western blot and flow cytometry have also been used. The use of Western 
blot is limited because no EV-specific protein marker is known. Commonly, 
CD63, Tsg101 and Alix are used to identify EXOs. The absence of proteins 
such as calnexin (from endoplasmic reticulum) is used as a negative control 
because it indicates no contamination by EVs from endoplasmic reticulum 
(Théry C A. S., 2006), (Lässer C E. M., 2012).  
Probably the most used technique is flow cytometry. It is very useful for 
high-throughput EV quantification and multiparameters characterization 
(van der Vlist EJ, 2012), but many flow cytometers are not able to analyse 
EVs due to their lower detection limit of 300-500 nm (Freyssinet JM, 2010) 
(Lacroix R., 2010). Often, to overcome this limit, authors bind EXOs to 
antibody-coated beads before flow cytometry. The antibody choice depends 
on EXO origins but antibodies able to recognize EXO common markers are 
often used (i.e. anti-CD63) (Lässer C E. M., 2012). 
Other very innovative systems are dynamic light scatter (DLS) and 
nanoparticle tracking analysis (NTA). They allow EV size determination 
through Brownian motion (van der Vlist EJ, 2012), (Tatischeff I, 2012), 
(Sokolova V, 2011). Even if several authors have favourably valuated these 
new techniques (van der Pol E H. A., 2010), (Filipe V, 2010), others feel 
that quantification of an EV pool of heterogeneous size is not precise and 
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only few parameters can be analysed at the same time (van der Vlist EJ, 
2012). 
There is an increased interest to analyse RNAs in subpopulations of 
extracellular vesicles because the EXO RNA differs from cellular RNA and 
probably, from that included in EVs. This characteristic may allow to 
distinguish different EV subpopulations and to evaluate contamination from 
different vesicles in a specific pellet. Using capillary electrophoresis, cells 
show two prominent RNA peaks corresponding to 18S and 28S rRNA 
subunits whereas EXOs lack prominent ribosomal RNA peaks and are 
enriched by smaller RNAs (Valadi H, 2007) (Lässer C, 2013). 
 
 
1.4 Extracellular vesicles: medical implications and 
therapeutic/diagnostic potential  
 
It is clear that EVs have metabolic effects on their target cells. This property 
supports their relevance in human disease (Anderson HC, 2010).  
Their involvement has been shown in ostheoarthritis (Ali SY, 1983), gastric 
ulcers and bacterial infection (Nowotny A, 1982), (Bhatnagar S, 2007), 
(Ismail S, 2003), (Kuehn MJ, 2005), atherosclerosis (Tanimura A, 1983), 
(Hsu HH, 1999), thromboembolic conditions (Chironi GN, 2009), (Cocucci 
E, 2009), hypertension (Daniel L, 2008) and cancer (Peinado H, 2012), 
(Taylor DD G.-T. C., 2011), (Zhu W X. W., 2006), (Zhu W H. L., 2012). 
In atherosclerosis, Hsu et al demonstrated that macrophages and intimal 
smooth muscle cells release MVs (Tanimura A, 1983), (Hsu HH, 1999). 
Rautou et al showed that vesicles from atherosclerotic plaques are able to 
transfer ICAM-1 to endothelial cells. This process induces phosphorylation 
of extracellular signal regulated kinase 1/2 and supports a role of EVs in 
atherosclerotic plaque progression (Rautou PE, 2011). 
Another well known MV role involves promotion of normal and 
pathological blood coagulation (Chironi GN, 2009), (Pásztói M, 2009). On 
their surface, MVs from platelets expose platelet-derived tissue factor and 
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von Willebrand’s factor, the major coagulation initiator (Dvorak HF, 1981). 
Therefore, EVs represent a surface in the assembly of the complexes 
involved in the coagulation cascade (Lentz BR., 2003).  
MVs have been involved also in thrombotic thrombocytopenic purpura, a 
disease characterized by thrombi formation in the microcirculation. MVs 
have procoagulant activity and induce microthrombi formation (Galli M, 
1996). It is not surprising that the MV number is increased in plasma from 
patients with this disease (Galli M, 1996).  
An increased amount of MVs is documented also in plasma from patients 
with chronic renal disease (Faure V, 2006). 
EVs role in cancer has been thoroughly studied. Tumour cells are able to 
constitutively release all types of EV subpopulations (György B S. T., 
2011). These EVs are involved in many tumour aspects such as tumour cell 
survival, growth, host invasion and metastasis. Moreover, they are able to 
evade host immunity (Valenti R, 2007). Thanks to their capability to 
transport and release proteases (Ginestra A, 1998), they promote tissue 
invasion. Local blood coagulation induced by EVs favours tumour cells 
adhesion to vessels (Dvorak HF, 1981). Tumour growth is supported by 
MVs expressing epithelial growth factor (Al-Nedawi K M. B., 2009) and 
tissue factors (Osterud B, 2003). The role of EVs has been studied in 
glioblastoma (Skog J, 2008), melanoma (Hood JL, 2009) and lung cancer. 
EXOs from lung cancer are enriched in specific miRNAs such as miR27, 
miR29, miR21 that are Toll like receptors agonists and are able to increase 
the inflammatory response. This process induces tumour growth and 
metastasis (Fabbri M, 2012). 
Taverna et al demonstrated that EXOs from chronic myelogenous leukemia 
cells induce angiogenesis (Taverna S, 2012). Umezu at al studied the ability 
of exosomal miR-92 from chronic myelogenous leukemia (K562) to induce 
cell migration and tube formation in human umbilical vein endothelial cells 
(HUVECs) (Umezu T, 2013).  
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The investigation of EV role in disease not only can be useful to better 
understand pathophysiology of diseases, but it also may open new 
perspectives for both diagnosis and therapy. 
 
Because of EXO specific tropism and their ability to transfer cargo to 
recipient cells, many researchers focused on EXO (and EVs in general) 
potential in therapies. EXOs are well tolerated by human body and have a 
long half-life in circulation (Lai RC, 2013). They can also overcome the 
blood-brain barrier (van den Goor JM, 2007). These characteristics give 
them a delivery potential for drugs and genes. For example, Sun et al have 
been able to load an anti-inflammatory drug (curcumin) in EXOs. They 
demonstrated that encapsulation of curcumin into exosomes increases its 
solubility, stability, and bioavailability (Sun D, 2010).  
Many studies dealt with genetic material delivery using EXOs: Ohno et al 
demonstrated that EXOs are able to release the anti tumour miR-let-7a to 
breast cancer cells that express EGFR (Ohno S, 2013). 
Other therapeutic EV applications derive from their ability to induce 
immune response against tumour. Maheveni et al demonstrated the ability 
of EXOs from melanoma and glioma cells to induce immune response and 
improve mice survival (Mahaweni NM, 2013). Other research groups used 
EXOs to treat malaria (Martin-Jaular L, 2011) or AIDS patients 
(Nanjundappa RH, 2011). Two clinical trials are ongoing (Escudier B, 
2005), (Morse MA, 2005). 
However, many challenges need to be dealt with, in particular the best 
technique to load EVs with drugs and how to target the cargo (Borges FT, 
2013). 
EVs are also considered potential biomarkers for disease diagnosis. Because 
EV protein marker and nucleic acid content reflects the nature and state of 
their parental cells, EVs are considered a precious source of information 
(Corrado C, 2013). For example Noerholm et al demonstrated that serum 
microvesicle RNA from patients with glioblastoma multiforme has 
significantly down-regulated levels of RNAs coding for ribosome 
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production, compared to normal healthy controls (Noerholm M, 2012). An 
increase of claudin-containig EXOs in blood is associated with ovaric 
cancer (Li J S.-B. C.-T., 2009). A mutant transcript of EGFR has been 
observed in plasma EXOs from glioblastoma patients (Skog J, 2008). 
All these possible applications require improvement in isolation and 
detection methods. 
 
 
1.5 Extracellular vesicles from blood samples 
 
Different subpopulations of extracellular vesicles have been reported in 
blood. Sometimes authors refer to blood EVs as microparticles (MPs) or 
cellular membrane microparticles. This term is not fully descriptive, but is 
often used (Freyssinet LM., 2003).  
Many studies documented the MP number variation in different pathologies 
and support their use in diagnostics. It is clear that MP release is a well 
controlled biological process. It has been demonstrated that platelets 
vesiculate in response to shear stress (Miyazaki Y, 1996) and storage (Bode 
AP, 1991). Combes et al demonstrated that a dramatic increase of MPs from 
platelets was observed when TNF-α promoting proapoptotic pathway was 
induced (Hamilton KK, 1990). 
 
1.5.1 Pre-analytical challenges 
 
Aiming to use MP analysis in diagnosis, pre-analytic variables need to be 
considered. 
Pre-analytic factors have not been extensively studied in literature. The MP 
release, especially from erythrocytes and platelets, is strongly sensitive to 
environmental factors. For this reason, all steps, from blood collection until 
analysis, need to be standardized. The variables that need to be considered 
are: the diameter of needle used for sample collection, way of collection 
(vacutainer, syringe, tube) and type of anticoagulant, storage temperature, 
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freeze-thaw cycles and analytic protocol (Simak J, 2006), (György B S. T., 
2011). Simak and Gelderman suggested that time between collection and 
isolation should be as short as possible. In that period, blood should be 
maintained at room temperature with gentle agitation (Simak J, 2006). 
Rubin et al demonstrated that erythrocyte EV concentration changes 
depending on agitation, storage time and temperature (Rubin O, 2010). 
Moreover, the number of Annexin V-positive MPs increases after several 
freeze-thaw steps in platelet-rich plasma (Connor DE, 2010).  
A crucial step in the centrifugation is represented by platelet depletion. MP 
lost and the induction of MP release from platelets and erythrocytes could 
depend on centrifugation protocol (Simak J, 2006).  
Shah et al demonstrated that just two centrifugation steps yield a high 
number of MPs as compared with a three steps centrifugation protocol. On 
the other hand, needle diameter does not seem to affect MP number.  
Citrate is generally used as anticoagulant. However, Shah et al showed that 
high levels of platelet- and erythrocyte-derived MPs were detected using 
heparin and Phe-Pro-Arg-chloromethylketone as anticoagulants as 
compared to citric acid-sodium citrate dextrose and sodium citrate (Shah 
MD, 2008). 
It is not often possible to process samples immediately after collection.  
Storage could create artefacts. Shah et al demonstrated a reduced number of 
MPs that are positive for AnnexinV/tissue factor after storage. On the other 
hand, the storage at -70 °C of platelet-free plasma for a couple of weeks 
does not influence MP analysis. A quick cycle of freeze-thaw is suggested 
because the prolonged incubation of samples at 37 °C could lead to 
deterioration of MPs and antigen loss (Shah MD, 2008).  
Generally, each laboratory develops its own assay to study MPs but 
different protocols of extraction, antibodies, and their clones have a 
dramatic impact on the results of MP analysis. Standardized procedures 
need to be implemented. 
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1.5.2 Methods of EV analysis in blood 
 
A lot of different methodological approaches have been used to analyse 
MPs from blood. Two methods are mostly used: 1) microparticle affinity 
assay and 2) flow cytometry. 
The first one is an ELISA assay based on antibodies able to recognize MP 
specific protein markers. A particular affinity assay uses Annexin V in 
presence of Ca2+ to recognize only MPs that are positive to 
phosphatidylserine (Simak J, 2006). This is a robust method, easy to use in 
the clinical setting and allows the analysis of a high number of samples at 
low cost. However, it does not allow MP quantification. Only “quality” 
information is obtained, no information about size and granularity. 
Furthermore, the MP positivity to phosphatidylserine is under discussion. 
Although it has been used as a typical MP marker, recent studies suggest the 
presence of Annexin V-negative MPs. Connor et al demonstrated that more 
than 80% of platelet-derived MPs in blood are Annexin V-negative (Connor 
DE, 2010). 
Flow cytometry (FACS) is the most common used approach to MP analysis, 
although the commonly used instruments cannot analyse MPs with a size 
less than 300-500 nm (Freyssinet JM, 2010). It allows the rapid analysis of a 
large number of MPs and provides information about size and granularity. 
Using labelled antibodies to recognize specific MP antigens, it can 
distinguish MPs shed from different cellular populations (Shah MD, 2008). 
However, results should be interpreted carefully. György et al demonstrated 
that during MP flow cytometry acquisition, immune complexes are formed 
and may be detected. Furthermore, when indirect labelling is used, they 
showed that primary and secondary antibodies form immunocomplexes 
detected in the MP gate and may hamper interpretation. To avoid 
immunocomplex formation these authors suggest to use direct 
immunolabelling (György B M. K., 2011).  
The use of FACS needs instrument calibration before MP analysis. Size 
beads of different diameters may be used to evaluate MP size (Simak J, 
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2006). Fluorescent beads of standardized size are produced by different 
companies (Becton Dickinson, Sigma, BioCytex). Generally, three bead 
diameters are used and MP gate is chosen accordingly (Robert S, 2009).  
FACS allows quantification of MPs that are positive for specific protein 
markers. Two methods are generally used: 1) the flow rate method is based 
on the number of MPs detected in a settled time (Nantakomol D, 2008); the 
analysis of biological samples with different viscosities is unfeasible 
(Orozco AF, 2010); 2) TruCountTM tubes (Becton Dickinson) contain a 
lyophilized pellet that dissolves during sample preparation releasing a 
known number of fluorescent beads, that allow calculation of the absolute 
MP number. 
The TruCountTM tubes major benefit is that the amount of labelled-beads is 
not introduced by the operator, eliminating a possible technical error. The 
absolute MP number is calculated from the number of events in MP and 
TruCountTM bead gate, total number of TruCountTM beads in the tube and 
the volume where the sample and beads have been re-suspended (Shet AS, 
2003), (Jayachandran M, 2009). It is the most thorough system to analyse 
the absolute MP number. On the other hand, it could be expensive 
depending on the sample number (Orozco AF, 2010). Flow cytometry is the 
best candidate to be considered as the “gold standard” for MP analysis 
(Gelderman MP, 2008). 
 
1.6 Erythropoiesis and erythroid progenitor markers     
 
The hematopoietic system ensures the production of the different cell types 
that compose the human blood. The continuous blood cell production is 
guaranteed by pluripotent stem cells (HSC) that are progressively 
committed to multipotent progenitors and evolve to committed progenitors 
(Testa U., 2004).  
In particular, erythropoiesis is a multistep process that leads HSC to 
differentiate in erythrocytes, cells specialized for oxygen transport.  
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The first step is the differentiation of HSC in hematopoietic progenitors 
named CFU-GEMM. Subsequently, they evolve to committed erythroid 
progenitors, i.e. erythroid burst-forming units (BFU-e) and erythroid 
colony-forming units (CFU-e). Then erythroid precursors with a 
characteristic morphology are formed. The first identifiable erythroid 
precursor is the proerythroblast, a cell characterized by a large nucleus, 
basophilic nucleoli and cytoplasm. Through several cell divisions they 
evolve first to the basophilic erythroblast, then to the polychromatophilic 
erythroblast and to the orthocromatic erythroblast. During these steps size is 
reduced, chromatin is condensed and sensitivity to erythropoietin (EPO) 
appears because EPO receptors are expressed (Testa U., 2004). Finally, the 
orthocromatic erythroblast loses its nucleus and becomes a reticulocyte, a 
non-nucleated cell with remnants of Golgi and endoplasmatic reticulum 
compartments. 
After a brief stay in bone marrow (R1), it passes through the endothelial 
wall of marrow sinuses and reaches blood circulation (R2) (Videl M., 2010). 
Here it becomes an erythrocyte, a biconcave disk without nucleus and 
organelles that contains mostly haemoglobin.  
Erythroid differentiation is based on a well regulated transcriptional process 
which result in the different expression of specific antigens (Santos PM, 
2011). These antigens can be used to identify differentiation stages and to 
distinguish the different committed precursors. FACS analysis allows to 
evaluate many antigens at the same time (Fig. 5).  
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Fig. 5: Maturation during erythropoiesis. The most representative markers 
expressed during erythroid maturation steps are indicated. The intensity colour 
variation corresponds to expression levels. 
 
 
CD34 is a marker of activated early progenitors (HSC and CFU-GEMM) 
and committed erythroid progenitors (BFU-e and CFU-e) (Furness SG, 
2006). Being a marker expressed only by activated progenitors its principal 
function is to promote HSC proliferation due to its anti-adhesion property. 
CD34 expression levels slowly decrease and it is absent in proerythroblasts. 
BFU-e and CFU-e express also CD117 (proto-oncogene c-Kit) (Andre C, 
1997). CD117 expression decreases during development. It is still 
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expressed, at low levels, by proerythroblasts. Proerythroblasts are, also, 
characterized by CD105 and CD71. The first one is member of TGFβ 
receptor complex involved in TGFβ modulation signalling as well as 
cytoskeletal organization (Sanz-Rodriguez F, 2004). CD105 is expressed 
also by basophilic erythroblasts, but at low levels. On the other hand CD71 
levels increase from proerythroblast to orthocromatic erythroblast when it is 
expelled by reticulocytes through vesicle formation (Fajtova M, 2011). 
CD71 is the cluster differentiation name for transferrin receptor protein 
(TFR), a membrane glycoprotein whose function is to mediate cellular 
uptake of iron from transferrin.  The highest amount of transferrin receptor 
is found on erythroid cells because they need to acquire iron for 
haemoglobin synthesis. It is released from reticulocytes during their 
maturation in erythrocytes by EXO secretion (Ponka P, 1999).  
The last marker to be expressed is CD235a (glycophorin A). It appears at 
the proerythroblast stage and its expression increases through maturation 
being the highest in erythrocytes (Fajtova M, 2011). Glycophorin A is one 
of the sialoglycoproteins that are expressed on red blood cell membranes. It 
is the major contributor to the negative surface charge of red blood cells. 
This negative charge is important for red cells interaction with the vascular 
endothelium (Griffiths RE, 2012). 
Fajitova et al identified antigen CD36 as a marker of late differentiation. It 
is expressed mostly on basophilic erythroblasts, but also on 
proerythroblasts, polycromatophilic and orthocromatic erythroblasts. The 
same authors identified CD38 and CD45 in both preoerythroblasts and 
basophilic erythroblasts (Fajtova M, 2011) although these are typical 
markers of immune cells (Jackson DG, 1990), (Brown VK, 1994). 
 
1.6.1 Extracellular vesicles from reticulocytes 
 
During maturation, a remodelling of plasma membrane is observed with 
reduction of cell volume and surface area (Géminard C d. G., 2002). 
Autophagy and membrane shedding have been shown to be involved in this 
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process (Seelig LL., 1972), (Simpson CF, 1968). More recently, Johnstone 
et al demonstrated that vesicle secretion is the principal process (Johnstone 
RM M. A., 1991), (Pan BT J. R., 1983). Johnstone and Stahl demonstrated 
that TFR shedding is associated to small vesicle release in reticulocytes 
maturation (Pan BT J. R., 1983), (Harding C, 1983). It now is apparent that 
EXO secretion during reticulocyte maturation is an integral part of the red 
cell development program (Blanc L V. M., 2010). Considering that EXOs 
have a diameter around of 60 nm, each reticulocyte releases between 800 to 
2600 EXOs equivalent to 1014 EXOs released every day in circulation 
(Blanc L D. G.-B., 2005).  
TFR is, of course, the most studied protein released in EXOs. During 
reticulocyte maturation this receptor is internalized into the cells through 
coated pits. Then it can be recycled to plasma membrane or segregated in 
multivesicular endosomes (Fig. 6). Multivesicular bodies evolve and release 
TFR positive EXOs (Géminard C d. G., 2002). Huebers et al demonstrated 
that the concentration of TFR reflects erythropoiesis rate. For this reason 
patients affected by erythroid hypoplasia induced by marrow-suppressive 
drugs showed a low amount of TFR as compared with controls (Huebers 
HA, 1990). Furthermore, EXOs released by reticulocytes are enriched with 
lipid and proteic markers. Beside lipid rafts (de Gassart A, 2003), other 
molecules are released with EXOs, including AChE, a glycosylphosphatic-
dylinisitol-anchored protein (Johnstone RM A. M., 1987), as well as CD55 
and CD59, whose loss has been observed in patients with paroxysmal 
nocturnal hemoglobinuria (Ware RE, 1995). Other EXO markers, such as 
hsc70 and Alix, have been observed in EXOs released from reticulocytes. 
They follow the TFR fate. Hsc70 has been demonstrated to interact with 
TFR during proteasome degradation (Géminard C D. G., 2004), whereas 
Alix interacts with TFR cytosolic domain and with ESCRT machinery 
involved in multivesicular body formation (von Schwedler UK, 2003). 
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Fig 6: TFR pathway during reticulocyte maturation. Modified from Blanc L et al, 
2005. 
 
 
Exosomal secretion is an integral part of erythropoiesis (Blanc L V. M., 
2010). Vesicles could be involved in all passages of erythroid progenitor 
maturation. Further studies are needed to investigate this exciting possibility 
and to ascertain whether impairment EV secretion could be involved in 
pathophysiology of red blood cell disorders.  
 
 
1.7 Extracellular vesicles released during cellular stress – p53 
involvement  
 
Cells are subjected to many different endogenous and exogenous stress 
types. Many responses have been developed to address each stress type, 
such as cell cycle arrest, apoptosis, senescence, autophagy (Yu X R. T., 
2009).  
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In the last ten years the role of EVs in the development of adaptive 
mechanisms against stress conditions has been demonstrated 
(Kucharzewska P, 2013). Much of what we know about the EV function in 
stress is gathered from studies focused on cancer. As already described, 
many authors showed that EVs are involved in tumour progression 
mechanisms, such as angiogenesis and metastasis (Kucharzewska P, 2013). 
Furthermore, several studies described cell vesiculation in response to 
different stress types such as hypoxia (Wysoczynski M, 2009), (Zhang HC, 
2012), (King HW, 2012), low PH level (Parolini I, 2009), oxidative stress 
(Eldh M, 2010), (Hedlund M, 2011), (Zhan R, 2009), thermal stress (Zhan 
R, 2009), (Clayton A T. A., 2005), (Chen T, 2011), radiation (Wysoczynski 
M, 2009), shear stress (Miyazaki Y, 1996) and drug effects (Lv LH, 2012). 
It is well documented that stress conditions on parental cells affect the EV 
content. For example, Choi and co-workers demonstrated that EVs released 
by primary cells have a very different protein cargo when compared with 
EVs shed from metastatic cells (Choi DS, 2012). In hypoxic conditions, the 
EXO amount shed from carcinoma cells (Park JE, 2010) as well as human 
and murine lung cancer cell lines (Wysoczynski M, 2009) is increased. 
These EXOs are enriched with proteins potentially able to modulate tumour 
microenvironment. In breast cancer cell culture increased amount of EXOs 
depends on HIF-1α. These EXOs are enriched with miR-210, a short RNA 
well known to be regulated by hypoxia (King HW, 2012). Mesenchymal 
stem cells release EVs that are similar to those shed by parental cells, but 
the majority of them are negative for platelet-derived growth factor receptor 
(Zhang HC, 2012).  
Regarding EV response in low PH conditions, Taraboletti et al 
demonstrated that EVs containing VEGF were destroyed under acidic pH 
conditions (a characteristic of the tumour microenvironment). 
Consequently, VEGF release led to significantly higher stimulation of cell 
motility (Taraboletti G, 2006). Moreover, in the same conditions, EVs 
released from melanoma cells have a less flexible membrane due to a 
different lipid composition. They are enriched with ganglioside GM3 and 
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sphyngomyelin. These lipids seem to bestow on EVs a better ability to fuse 
with plasma membrane of recipient cells (Parolini I, 2009). Eldh et al 
showed that oxidative stress induce a massive change in mRNA content in 
EXOs from mast cell lines. Furthermore, EXOs are able to confer resistance 
against oxidative stress and viability improvement in recipient cells (Eldh 
M, 2010). 
Levine and co-workers have investigated the role of p53, a transcriptional 
factor activated by a wide variety of stress signals. It acts to restore cellular 
homeostasis and prevents the accumulation of errors on DNA changes 
(Levine AJ., 1997). In 2006, Yu et al observed that, after p53 activation, 
several proteins encoded by genes that are not p53 transcriptional targets, 
increased in the cell medium of non small cell lung cancer cell line (H460) 
and they were released through EXOs. They discovered that the p53 role in 
EXO production is linked to the expression of a p53 gene target: TSAP6 
(Yu X H. S., 2006). TSAP6 is involved in proteins transport (Roperch JP, 
1998). Two years later, Telerman and collaborators provided the first 
genetic evidence that exosome formation is a tightly controlled biological 
process dependent of TSAP6. TSAP6 deficient mice show microcytic 
anemia (reticulocytes and erythrocyte were smaller with abnormal shape 
and osmotic fragility). Reticulocytes from these mice could not expel TFR 
during their maturation (Lespagnol A, 2008). Absence of TSAP6 resulted in 
a deficiency of EXO formation delaying the maturation of bone marrow 
erythroblasts and reticulocytes. Another p53 gene target, CHMP4C, is 
known to be involved in EXO production. It is part of the ESCRT-III 
protein complex that is essential for endosome formation (Yu X R. T., 
2009). However, a p53 independent mechanism has been shown. An 
accumulation of ceramide, a lipid molecule involved in EXO formation 
(Trajkovic K, 2008), has been shown in response to different stress types 
(Nikolova-Karakashian MN, 2010). It could be interesting to evaluate 
whether stress-induced ceramide accumulation is paralleled by increase 
EXO production.  
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1.8 Ribosomal stress: cell proliferation inhibition through 
p53-dependent and -independent mechanisms 
 
p53 activation is induced by cells exposed to different stress types as UV 
radiation, heat shock, hypoxia (Horn HF, 2007). Also an aberrant ribosome 
biogenesis leads to increased p53 levels. This condition is named 
“ribosomal stress” (or “nucleolar stress”) (Pestov DG, 2001), (Rubbi CP, 
2003).  
Ribosome biogenesis occurs in the nucleolus and is the result of coordinated 
steps that include rRNA precursor processing. Briefly, RNA polymerase I is 
involved in transcription of 47S rRNA precursor. The processing of this 
precursor generates the mature 18S, 5.8S and 28S rRNA, whereas 5S RNA 
is transcribed independently. rRNA and ribosomal proteins (RPs) are 
collected in a specialized cellular compartment: the nucleolus, where rRNA 
and RPs are assembled to form the large 60S and the small 40S subunits. 
Finally, the subunits are exported to the cytoplasm (Lempiäinen H, 2009).  
Perturbation to this complex process includes inadequate rRNA 
transcription, disruption of rRNA procession or RP imbalance. These 
abnormalities trigger ribosomal stress followed by p53 activation 
(Deisenroth C, 2010). p53 activity is regulated by the MDM2 oncoprotein 
that binds to p53 and targets it to degradation. Under normal condition p53 
levels are low because it is constantly degraded through MDM2 interaction. 
In many stress conditions, the interaction MDM2-p53 is disrupted and p53 
levels increase (Olausson KH, 2012).  
Several tumour suppressor proteins, such as ARF, have been demonstrated 
to bind MDM2 and inhibit MDM2-p53 interaction (Zhang Y X. Y., 2001). 
Several RPs are able to bind MDM2 inducing increased p53 levels. “Free” 
RPs are available to bind MDM2 as consequence of altered ribosome 
biogenesis (Zhang Y L. H., 2009) (Fig. 7). 
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Fig. 7: Schematic p53-dependent mechanism induced by ribosomal stress. 
Modified from Zhang Y et al, 2009. 
 
 
Several studies demonstrated that several RPs, such as RPL5 (Dai MS L. H., 
2004), RPL11 (Zhang Y W. G., 2003), (Lohrum MA, 2003), (Bhat KP, 
2004), RPL23 (Dai MS Z. S., 2004), (Jin A, 2004) and RPS7 (Chen D, 
2007) could bind MDM2 and inhibit its E3 ubiquitin ligase function.  
However, beside p53-dependent pathways, recently a p53-independent 
mechanism of cell arrest in response to abnormal ribosome biogenesis has 
been documented (Donati G M. L., 2012). Firstly discovered in Drosophila 
(Grewal SS, 2007), it has been better documented in recent years. In 2009, 
Li at al investigated the role of pescadillo, a protein involved in processing 
of pre-rRNA molecules. They demonstrated that knockdown of this protein 
results in cyclin D1 down-regulation and cyclin-dependent kinase inhibitor 
p27/Kip1 up-regulation (Li J Y. L., 2009).  
Furthermore, a PIM1-dependent pathway has been suggested. Iadevaia et al 
demonstrated that RPs deficiency caused down-regulation of PIM1 
expression. Down regulation of RPS19 and other RPs induced PIM1 
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proteasome degradation. PIM1 is a serine/threonine kinase that reduces the 
activity of p27/Kip1. PIM1 reduction induces p27/Kip1 stabilization and 
blocks the cell cycle regardless p53 (Iadevaia V, 2010).  
The role of RPL11 in p53-independent mechanisms has been investigated. 
Inhibiting rRNA transcription, RPL11 protein is “free” and binds MDM2. 
The result is that E2F-1 protein is not blocked by MDM2 and can induce 
expression of E2F gene targets that are necessary for the progression 
through cell cycle (Donati G B. E., 2011). Furthermore, RPL11 together 
with RPL5 is able to bind c-Myc, a well documented cell proliferation 
stimulator. The binding of RPL11 to c-Myc induces reduction of c-Myc 
transcription and c-Myc degradation followed by reduced cell proliferation 
(Liao JM, 2013).  
 
 
1.9 Diamond Blackfan Anemia (DBA), a human disease due 
to ribosomal stress  
 
Mutations in genes encoding for RPs have been identified as the cause of 
human genetic diseases. Diamond Blackfan Anemia (DBA) is the first 
human disease shown to be caused by a defect in ribosomal proteins 
(Draptchinskaia N, 1999). It is a congenital bone marrow failure syndrome 
due to a specific defect of the erythroid lineage (Hölzel M, 2010). This 
haematological disorder is member of a class diseases known as 
“ribosomophaties”, characterized by genetic anomalies resulting in 
defective ribosome biogenesis (Raiser DM, 2013). DBA pathogenesis is due 
to ribosomal stress triggered by an abnormal ribosome biogenesis. 
 
1.9.1 Clinical features and molecular basis 	  
DBA (MIM 105650) is categorized as a congenital bone marrow failure 
syndrome, presenting during infancy with an incidence of 4-5 cases/one 
millions live births (Orfali KA, 2004). It is a hypoplastic anemia 
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characterized by other haematological characteristic as macrocytosis, 
reticulocytopenia, high activity of adenosine deaminase (ADA) in red cells 
(Lipton JM, 2009). Defective erythropoiesis is revealed by a very low 
number of erythroid precursors and, functionally, by a reduction of BFU−E 
progenitor cells in the bone marrow. It shows autosomal dominant 
transmission (Campagnoli MF G. E., 2004). Proliferative and differentiative 
activity towards the other lineages is normal.  
Beside these haematological characteristics, half of patients show physical 
abnormalies as short stature, thumb abnormalies, heart defect, craniofacial 
abnormalies and cleaft lip and palate (Lipton JM, 2009). 
Standard therapy consists in steroids; about 40% of patients respond to this 
therapy. The non-responsive patients are treated with red blood cell 
transfusion, but stem cell transplantation is the only definitive treatment 
(Vlachos A M. E., 2010). Twenty per cent of patients develop a clinical 
remission, but the biological reasons are unknown (Quarello P, 2010). 
DBA shows an autosomal dominant inheritance and all mutated genes have 
heterozygous mutations (Ball S., 2011). RPS19 is the first DBA gene 
identified (Draptchinskaia N, 1999). Mutations in RPS19 have been found 
in 25% of patients (Campagnoli MF R. U., 2008). Ten genes encoding 
ribosomal proteins have been found mutated in DBA patients, i.e. RPS19, 
RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS26, RPS10, RPL26 
(Draptchinskaia N, 1999), (Gazda HT G. A.-L., 2006), (Cmejla R, 2007), 
(Gazda HT S. M., 2008), (Farrar JE, 2008), (Doherty L, 2010). The most 
frequently mutated genes, after RPS19, are RPL5 and RPL11 that account 
for 10% of DBA patients (Gazda HT G. A.-L., 2006). About 60% of 
patients show mutations in genes encoding ribosomal proteins. Extra-
ribosomal factors have been speculated to have a role in those patients that 
are mutation-negative for RP genes. GATA-1, encoding for a hematopoietic 
transcription factor has been found mutated in four patients with DBA 
(Sankaran VG, 2012), (Parrella S, 2014).  
Several studies in Drosophila, Xenopus, Zebrafish and mouse showed that 
p53 activation is involved in DBA development (Kongsuwan K, 1985), 
1.	  Introduction	  
	   31	  
(Miller L, 1970), (Danilova N, 2008), (McGowan KA, 2008). As already 
said, the insufficient RP production could lead to excess of other RPs that 
can interact with MDM2 inducing cell cycle arrest (Zhang Y L. H., 2009). 
However, the role of p53 in DBA pathogenesis is still under discussion. 
Also p53-independent mechanisms have been suggested. Both p53-
dependent and -independent mechanisms may cooperate and induce cell 
cycle arrest with a proapoptotic phenotype in erythroid progenitors. 
 
1.9.2 Global gene expression in p53 null-cell models of DBA suggests 
activation of p53-independent pathways (Aspesi et al, submitted to 
Gene) 
 
Defects in ribosome synthesis have been shown to activate p53 thereby 
providing a rationale for the pro-apoptotic phenotype of erythroid 
progenitor in DBA (Draptchinskaia N, 1999), (Vlachos A B. S., 2008). p53 
inhibition has been demonstrated to attenuate the proapoptotic phenotypes 
in DBA models (Drosophila, Xenopus, zebrafish and mouse) (Kongsuwan 
K, 1985), (Miller L, 1970), (Danilova N, 2008), (McGowan KA, 2008). 
However, p53 inhibitors cannot be used in therapy because of their risk of 
cancer development. We considered that identification of p53-independent 
pathways could suggest more realistic treatments for DBA. To this aim, we 
analysed the gene expression changes in three p53-null cell models of DBA 
as compared with the appropriate controls. Using a microarray approach 
(Affimetrix GeneChip Human Genome U133A) followed by sophisticated 
statistical analysis (ranking-PCA), a set of dysregulated genes that are 
common to the three DBA cell models has been identified. The Gene 
Onthology classification showed an enrichment of genes involved in amino 
acid metabolism, negative regulation of cell proliferation, apoptosis and cell 
redox homeostasis whereas PANTHER Biological annotation identified 
genes involved in haematopoiesis and amino acid/steroid metabolism. Our 
results demonstrated that gene expression is altered in DBA cell models in 
agreement with the proapoptotic phenotype observed in DBA. The 
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manuscript is attached. 
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In the last years, the field of extracellular vesicles (EVs) has been 
characterized by an increasing interest due to their possible use as 
biomarkers for different diseases and their therapeutic potential. 
However, a great challenge still needs to be solved, i.e. the standardization 
of methods used to separate EV subpopulations. It is crucial to distinguish 
the different EV subpopulations to avoid cross contamination that could 
lead to data misinterpretation. 
Therefore, the first aim of this thesis has been to analyse different isolation 
methods to obtain the following objectives: 
1. To evaluate the potential of centrifugation-based protocols to 
separate apoptotic bodies, microvesicles and exosomes and 
characterize them by RNA profile analysis, electron microscopy and 
flow cytometry. 
2. To analyse the effect of a filtration step on exosome pellet purity, 
looking at the RNA profile of the isolated exosomal fractions. 
3. To compare the different EV populations obtained using protocols 
detailed at points 1 and 2 and looking at their RNA profiles. 
A significant numbers of studies focused on the role of EVs in response to 
biological stress (hypoxic conditions, low pH level, oxidative stress, thermal 
stress, radiation, shear stress and drugs effect). However, nobody has 
analysed EV release during ribosomal stress. Diamond Blackfan Anemia 
(DBA) is a disease due to abnormal ribosome biogenesis that induces 
apoptosis in erythroid progenitors. DBA research is hampered by the 
inability to study erythroid progenitors. The characterization and 
quantitative analysis of EVs from erythroid progenitors could be useful to 
overcome this limitation. The following objectives were attempted: 
4. To investigate the miRNAs pattern in EVs shed by a DBA cell 
model. 
5. To characterize and quantify microparticles from erythroid 
progenitors released in blood of patients with Diamond Blackfan 
Anemia.   
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3.1 Isolation and characterization of EVs: RNA profile 
analysis distinguishes EV subpopulations 
 
The EV field is rapidly expanding, but isolation methods, classification and 
quality assessment methods are still under discussion (Simpson RJ., 2012). 
EV isolation methods are based on sedimentation time, density, size and 
surface markers that are different in EV subpopulations. Despite distinct 
features, numerous similarities exist among different EVs so the overlap and 
pellet “contamination” could be greater than believed.  
 
 
3.1.1 Centrifugation based protocols to separate ABs, MVs and EXOs  
(Crescitelli et al, 2013) 
 
This project was performed at Krefting Research Centre, Department of 
Internal Medicine, University of Gothenburg, Sweden under the supervision 
of Prof. Jan Lötvall. 
Our aim was to properly separate subpopulations of extracellular vesicles 
and analyse their different molecular characteristics.  
We compared a differential centrifugation-based protocol used to isolate 
ABs and MVs (protocol 1) (Turiák L, 2011) and another protocol to isolate 
EXOs after removal of ABs and MVs (protocol 2) (Valadi H, 2007). In 
short, for both of protocols, cells were harvested and pelleted by 
centrifugation at 300 × g, vesicles were collected from the supernatant at 
differential centrifugation steps. 
Protocol 1: ABs were collected at 2000 × g. Supernatant was filtered 
through 0.8 µm pores and MVs were pelleted by ultracentrifugation at 
12200 × g. 
Protocol 2: ABs and MVs were collected together at 16500 × g. Supernatant 
was filtered through 0.22 µm pores and EXOs were pelleted by 
ultracentrifugation at 120000 × g. 
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We utilized these protocols to isolate different vesicles from supernatant of 
three cell lines (HMC-1, TF-1 and BV-2). First of all, EV RNA profiles 
were analysed. We demonstrated that distinct vesicle fractions have clearly 
different RNA profiles. rRNA was primarily detected in ABs  from all cell 
lines, whereas little or no RNA was contained in MVs, except for those 
from TF-1 cells. In EXO, the RNA profiles from all cell lines lacked rRNA 
peaks, but showed small RNAs. In the pellet containing both ABs and MVs, 
RNA profiles similar to those observed for ABs, were observed in vesicles 
from all cell lines. To verify if the contribution to the rRNA in the 
ABs+MVs pellet was provided by ABs and not by MVs, a modification of 
protocol 2 was utilized. In this protocol, the 2000 × g step was added, 
aiming to separate ABs and MVs otherwise collected in the same pellet in 
the original protocol 2. The comparisons of the RNA profiles showed that 
the rRNA peaks were predominant in ABs from the HMC-1 and TF-1 cell 
lines. We can thus conclude that ABs are likely to contribute the majority of 
the rRNA present in the pellet composed by a mixture of ABs and MVs.	  
Considering that RNA content of EVs can change depending on the state of 
the cell, we analysed RNA profiles from EVs shed by cells subjected to 
TRAIL-induced apoptosis. We demonstrated that the RNA profile was 
maintained during apoptosis, but RNA concentration was increased in ABs, 
but also in EXOs. It is well known that EXO secretion is increased during 
apoptosis (Yu X H. S., 2006).  
Furthermore, electron microscopy revealed a morphology compatible with 
ABs, MVs and EXOs. Elements with chromatin condensation and 
marginalization and a size range of 800-5000 nm was present in the pellet 
composed by ABs; round and oval shaped, membrane-bound structures with 
a size between 200-800 nm characterized MVs and finally, EXOs showed 
cup shape with a diameter of 40-100 nm. As expected, the pellet composed 
by both ABs and MVs showed elements with 200-5000 nm diameter, with 
typical characteristics of both ABs and MVs. The pellets morphology 
characteristics were similar for pellets isolated from all three cell lines 
considered. This finding shows that separation was correctly achieved. 
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Finally, in order to better characterize the different subpopulations of EVs, 
flow cytometry-based evaluation of the tetraspanins CD9, CD63 and CD81 
was performed on vesicles from HMC-1 and TF-1 cells. CD9, CD63 and 
CD81 were considered specific for EXOs (Escola JM, 1998). We observed 
that all pellets contained vesicles captured by anti-CD63-coated beads. This 
shows that CD63 marker is not exclusively present on EXOs, as previously 
suggested (Escola JM, 1998), (Bobrie A C. M., 2012). CD63 positive 
vesicles were also positive for all other markers investigated except for CD9 
that was not expressed by TF-1-derived vesicles since TF-1 cells do not 
express this tetraspanin. Our results demonstrated that anti-CD63-coated 
beads and flow cytometry is not a robust method for EXO characterization. 
Our results, demonstrated that centrifugation-based protocols are simple and 
fast systems to distinguish subpopulation of EVs. Different EV types show 
different RNA profiles and peculiar morphological characteristics, but they 
are indistinguishable using anti-CD63-coated beads for flow cytometry. 
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3.1.2 Effect of filtration on the purity of exosome fraction: identification 
of two types of exosome-like vesicles 
 
This project was performed at Krefting Research Centre, Department of 
Internal Medicine, University of Gothenburg, Sweden under the supervision 
of Prof. Jan Lötvall. 
• Aim of the project 
The experiments in this section are part of a wide project whose aim was to 
evaluate the effect of filtration on the purity of the exosome fraction. We 
were interested to determine how the different centrifugation-based 
protocols affected the isolation of EV populations and their RNA profile. 
Differently from the first project whose aim was to evaluate the 
centrifugation effects of time and speed centrifugation steps, here we 
focused on the filtration step. Therefore we used the same EXO isolation 
protocol (Valadi H, 2007) with or without 0.22 µm filter. 
 
• Experimental plan and methods 
The effect of filtration was investigated in two different types of cells: 
erythroleukemia cell line TF-1 (ATCC: CRL-2003) and primary cells 
PBMC (Peripheral blood mononuclear cell). TF-1 were cultured in RPMI-
1640 supplemented with 10% foetal bovine serum (FBS), 100 units/ml 
penicillin, 100 µg/ml streptomycin 2 mM L-glutamine and 5 ng/ml 
granulocyte macrophage colony-stimulating factor (GM-CSF) (all reagent 
were from Sigma-Aldrich). PBMC were isolated from human buffy coat 
using Leucosep® Tubes (Greier Bio-One GmbH) according to the 
manufacturer’s protocol. After two washes in 2 mM EDTA in PBS, PBMC 
were cultured in RPMI-1640 supplemented with 10% FBS, 100 units/ml 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. The FBS was 
ultracentrifuged for 18 hours at 120000 × g to eliminate exosomes. Cell 
viability was determinated using the trypan blue dye method. Cells (TF-1 
and PBMC) were cultured for three days. At day three the conditional media 
was used for exosome isolation. Exosomes were isolated by a differential 
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ultracentrifugation protocol that was previously described (Valadi H, 2007) 
(Fig. 8A) and the fixed angle rotor, Ti45, was used. Half of the samples 
were filtered through a 0.22 µm filter, while the other half was unfiltered. In 
the filtered samples, two separate pellets were identified. One pellet was 
attached to the tube and corresponds to the standard exosome pellet and we 
called “exosomes without filter” (or “EXOs w/o filter”). The second pellet 
was non-fixed but was collected at the bottom of the tube. We will call 
“additional pellet” (Fig. 8B). The exosome enriched pellet was also found in 
the filtered samples and is here called “exosomes with filter” (“EXOs w 
filter”). The “additional pellet” was not detected in the sample were the 0.22 
µm filter was used. However, a sample was collected from the bottom of the 
tube, as a control (here named “Control region”) (Fig. 8B). To characterize 
the pellets isolated with and without filter, as well as the “Control region”, 
the total RNA was isolated using the miRCURYTM RNA isolation kit – Cell 
and Plant (Exiqon) according the manufacturer’s protocol and analysed on a 
RNA 6000 Pico Chip using an Agilent 2100 Bioanalyzer (Agilent 
Technologies) following the manufacture’s procedures.  
 
 
 
Fig. 8: A) Flow chart describes the differential centrifugation based protocol. Half 
of the supernatant is filtered through a 0.22 µm filter, while the other half is left 
unfiltered. B) A schematic representation of the different pellets identified using 
the protocol shown in figure A with or without the use of filter. 
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To further characterize and purify the different vesicle types isolated, the 
“EXOs w filter” and “additional pellet” from TF-1 cells were floated into a 
sucrose gradient. Sample was dissolved in 2.5 M sucrose and put in 
ultracentrifugation tubes. Then 15 consecutive 2.2 ml layers of decreasing 
sucrose concentrations in PBS (2-0.4 M) were layered on top of the sample. 
Gradients were ultracentrifuged for 16 hours; with no breaks at 4ºC in a SW 
rotor at 175000 × g. Ten fractions were collected and ultracentrifuged in 
PBS at 120000 × g for 70 min in Ti70 rotor. The ten pellets isolated from 
the sucrose gradient were resuspended in RNA lysis buffer and their RNA 
profile was analysed using the Bioanalyzer instrument as previously 
described.  
 
• Results and discussion 
The pellets were isolated as described and the RNA profiles were analysed. 
As showed in figure 9A, the exosome pellet from the sample that has been 
filtrated (“EXOs w filter”) contained mostly short RNAs and just small 
rRNA peaks whereas the sample that was not filtered (“EXOs w/o filter”) 
showed more evident rRNA peaks (18S and 28S). Interestingly, the 
“additional pellet” contained large rRNA peaks. The “control region” 
contained no rRNA peaks similarly to the adherent exosome pellet (“EXOs 
w filter”) but with lower RNA concentration. These results were confirmed 
in primary cells (PBMC) where RNA profile was very similar with that of 
TF-1 cells (Fig. 9B).  
It is clear that, when using 0.22 µm filtration step, vesicles containing rRNA 
are lost whereas the “additional pellet” obtained without filtration contain 
rRNA. Small rRNA peaks could be observed in the pellet attached to the 
wall (“EXOs w/o filter”), indicating a probable contamination from 
“additional pellet”.  
These data are consistent with other reports showing that EXO RNA profile 
is characterized by no or little rRNA, but enriched with small RNAs (Valadi 
H, 2007), (Miranda KC, 2010).  
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It could be interesting to investigate the effect of filtration using filters with 
different sizes. However, there is no consensus about the rRNA EXO 
content. Some studies demonstrated rRNA peaks in EXOs (Miranda KC, 
2010), others did not (Valadi H, 2007), (Lässer C A. V., 2011). Similarly, 
there is no consensus about using or not a filtration step and pore size. Our 
results demonstrated that the differences shown in exosome studies could be 
due not only to a different EXO origin, but also to the different filter used. 
Other explanations about differences in EXO RNA profiles could be due to 
the centrifugation rotor used: it is impossible to separate adherent and non 
adherent pellet using a swinging bucket rotor. Furthermore, particles size 
analysis could be useful to understand why “additional pellet” was stopped 
in the filter. It is possible that this behaviour was due to the higher size of 
the particles composing the “additional pellet”, but surface charge and 
protein composition need to be investigated. 
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Fig. 9: RNA profiles of “EXOs w filter”, “EXOs w/o filter”, “Control region” and 
“Additional pellet”. A) RNA profiles were analysed in the four pellets isolated 
from TF-1 cells B) and primary cells (PBMC: peripheral blood mononuclear cells). 
RNA profiles are representative of three experiments. 
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To further purify and characterize these pellets, the adherent pellet obtained 
with filtration (“EXO w filter”) and the pellet collected at the bottom of tube 
not using filter (“additional pellet”) were loaded on sucrose gradient and 
RNA profile was analysed. The results are shown in figure 10. In “EXO w 
filter”, small RNA was found in fractions 8-10 (1.24-1.31 g/cm3). The 
density range was calculated as the average of three different experiments 
(collaboration with Cecilia Lässer – Kreafting Research Centre, 
Gothenburg). Interestingly, the RNA from the additional pellet showed both 
rRNA-positive and -negative fractions. In particular, the rRNA peaks were 
mainly found in fractions 3-6, (1.12-1.21 g/cm3) whereas the small RNA 
peaks, similar to what observed in “EXO w filter”, were mainly detected in 
fractions 8-10. These results indicate that rRNA-negative vesicles have 
lower density, while the rRNA-positive vesicles have higher density. In 
conclusion, our data show that the inclusion of a sucrose gradient step after 
centrifugation allows a further vesicle separation.    
Although EXO density was considered to be between 1.13-1.19 g/cm3, 
several studies demonstrated that they have a higher density (Caby MP, 
2005), (Vella LJ, 2008). Our results show that EXO density could be 
different from what indicated so far.  
A lipidic and protein composition analysis needs to be done to better 
characterize these two exosome-like vesicles. 
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Fig. 10: RNA profiles from ten fractions obtained loading “EXOs w filter” and 
“Additional pellet” on a sucrose gradient. “EXO w filter” and “Additional pellet” 
were isolated from TF-1 cells supernatant. RNA profiles are representative of two 
experiments. 
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3.1.3 RNA characterization in EV subpopulations: RNA profile 
comparison between exosomes-like vesicles and ABs, MVs and EXOs 
 
This project was performed at Krefting Research Centre, Department of 
Internal Medicine, University of Gothenburg, Sweden under the supervision 
of Prof. Jan Lötvall. 
• Aim of the project 
The data presented in the previously fraction of this thesis show that EV 
subpopulations need to be further characterized and distinguished. The 
general perception is that authors often investigated the same type of 
vesicles, but called them in different ways. Furthermore, specific EV 
characteristics are still not well documented and we cannot exclude that 
similar features could be showed by different vesicle types. To investigate 
this hypothesis, we loaded the following subpopulations on sucrose 
gradient: ABs, MVs, EXOs (isolated using a centrifugation protocol) as well 
as “EXO w filter” and “additional pellet” obtained using and not using 
filter. We compared RNA profiles from ten fractions obtained from each 
samples.  
 
• Experimental plan and methods 
ABs, MVs and EXOs as well as “EXOs w filter” and “additional pellet”, 
were isolated from supernatant of TF-1 cells. TF-1 (ATCC: CRL-2003) 
were cultured in RPMI-1640 supplemented with 10% foetal bovine serum 
(FBS) 100 units/ml penicillin, 100 µg/ml streptomycin 2 mM L-glutamine 
and 5 ng/ml GM-CSF (all reagent were from Sigma-Aldrich). The FBS was 
ultracentrifuged for 18 hours at 120000 × g to eliminate exosomes. Cells 
were cultured for three days. At day three the conditional media was used 
for EV isolation. ABs, MVs and EXOs were isolated by a differential 
ultracentrifugation protocol. A modified protocol from Valadi et al (Valadi 
H, 2007) was used (protocol A). Briefly, the 2000 × g step was added to the 
original protocol, aiming to separate ABs and MVs otherwise collected in 
the same pellet in the original protocol (Fig. 11A). Protocol B was used to 
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obtain “EXO w filter” and “additional pellet” with or without a 0.22 µm 
filter as described in the previous section (Fig. 11B). Protocols A and B 
were described in Crescitelli et al 2013 and in the previously section of this 
thesis. 
 
 
 
Fig. 11: Flow chart reporting two differential centrifugation-based protocols. A) 
ABs, MVs and EXOs are isolated at different centrifugation steps using protocol 
A. B) Protocol B is used to isolate EXO pellet including 0.22 µm filtration step. 
The same protocol is applied without a filtration step to isolate EXOs (“EXOs w/o 
filter”) and “Additional pellet”. 
 
EVs collected were floated into a sucrose gradient. Pellets were resuspended 
in 2.5 M sucrose in PBS and transferred to ultracentifugation tubes. Fifteen 
consecutive 2.2 ml layers of decreasing sucrose concentrations in PBS 
(from 2-0.4 M) were layered on top of the samples. Gradients were 
ultracentrifuged for 16 hours, with no breaks at 4ºC in a SW rotor at 175000 
× g. Ten fractions were collected and ultracentrifuged in PBS at 120000 × g 
2,000$x$g,$20$min$=$ABs$
16,500$×$g,$20$min$=$MVs$
0.22$μm$filter$
300$×$g,$10$min$
16,500$×$g,$20$min$$$
0.22$μm$filter$
Protocol$B$B)$A)$ Protocol$A$
300$×$g,$10$min$
120,000$×$g,$70$min$$
EXOs$
Valadi$H.$et#al#Nat$Cell$Biol.$2007$Crescitelli$R.$et#al#JEV.$2013$
120,000$×$g,$70$min$$
EXOs/addi/onal$pellet$
3.	  Results	  and	  discussion	  	  
	   82	  
for 70 min in Ti70 rotor. The total RNA was isolated from ten pellets using 
the miRCURYTM RNA isolation kit – Cell and Plant (Exiqon) according the 
manufacturer’s protocol and analysed on a RNA 6000 Pico Chip using an 
Agilent 2100 Bioanalyzer (Agilent Technologies) following the 
manufacturer’s procedures. 
 
• Results and discussion 
The RNA profile analysis of the ten AB fractions showed that all of them 
contain RNA but with the different profiles (Fig.12). This heterogeneity 
parallels the morphological heterogeneity shown at electron microscopy 
(Crescitelli R. 2013, Fig. 5 A1-A3). The rRNA is only contained in fraction 
4-6 with very small peaks. This is very far from what expected. ABs pellet 
are known to contain very prominent rRNA peaks (Crescitelli R, 2013), but 
these experiments show that the rRNA peaks are not so evident. rRNA 
could be outside of vesicles. If this is the case, rRNA not protected by lipid 
membrane, could be degraded during the sucrose layers preparation and the 
very long centrifugation. Regarding density, our results are consistent with 
Thery et al that described AB density between 1.16-1.28 g/cm3 (Théry C B. 
M.-C., 2001).  
MV density is not known. Sucrose gradient was performed and RNA 
profiles from ten fractions analysed. The comparison with fractions 
separated from “additional pellet” is shown in figure 13. MV pellet seems to 
include two different kinds of vesicles. When loaded on sucrose gradient, 
rRNA-positive vesicles were identified mainly in fractions 2-7 (1.12-1.23 
g/cm3) similar to what observed in “additional pellet”, whereas RNA-
negative vesicles were found in lower fractions 8-10 (1.24-1.31g/cm3), as 
showed for “additional pellet”. MV and “additional pellet” fractions seem to 
be very similar in vesicle composition (rRNA-positive and rRNA-negative 
vesicles), but MV pellet seems to be more heterogeneous. In the “additional 
pellet”, two vesicle populations appear well separated (fractions 2-6 (1.09-
1.23 g/cm3) rRNA-positive vesicles, fractions 8-10 (1.24-1.31 g/cm3 ) 
rRNA-negative vesicles).  
3.	  Results	  and	  discussion	  	  
	   83	  
In these experiments, pellets have been extracted from TF-1 cells 
supernatant. In agreement with results showed in Crescitelli et al, 2013, 
MVs from TF-1 cells show rRNA peaks. Since MVs from HMC1 cells did 
not contain rRNA peaks (Crescitelli R, 2013), it should be interesting to 
compare RNA profiles in MV and “additional pellet” fractions shed from 
HMC1 cells where the absence of rRNA is expected (Crescitelli R, 2013). 
Fractions obtained from EXO pellet are composed only by rRNA-negative 
vesicles and they were found in fractions 8-10, the same rRNA-negative 
fractions were detected in “EXO w filter” loaded on sucrose gradient (Fig. 
14). This result was expected because the protocols used were exactly the 
same at this centrifugation step (120000 × g after filtration step). 
The results confirmed that there is a density overlap between different 
vesicles. This underlines the nomenclature problem. In fact, what we 
indicated as MVs using protocol A seems to be the same pellet extract using 
protocol B (“additional pellet”) without filtration step (Fig. 8 and Fig. 11). 
In conclusion, the isolation and characterization of EV subpopulations is a 
still open challenge. Other investigations such as transcriptomic and 
proteomic analyses may be used to distinguish different vesicle types. 
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Fig. 12: RNA profiles from ten fractions obtained after loading AB pellet on 
sucrose gradient. ABs were extracted from TF-1 cells supernatant. RNA profiles 
are representative of two experiments. 
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Fig. 13: RNA profiles from ten fractions obtained after loading MV pellet on 
sucrose gradient. The comparison with the fraction obtained from “Additional 
pellet” is shown. MVs and “Additional pellet” were extracted from TF-1 cells 
supernatant. RNA profiles are representative of two experiments. 
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Fig. 14: RNA profiles from ten fractions obtained after loading EXO pellet on 
sucrose gradient. The comparison with fractions obtained from “EXO w filter” is 
shown. EXOs and “EXOs w filter” were extracted from TF-1 cells supernatant. 
RNA profiles are representative of two experiments. 
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3.2 Study of extracellular vesicles in ribosomal stress  
 
Vesicle production is induced by p53 activation in response to different 
stress types (hypoxia, low PH level, oxidative, thermal stress, radiation, 
shear stress and drugs effect) (Wysoczynski M, 2009), (Zhang HC, 2012), 
(King HW, 2012), (Parolini I, 2009), (Eldh M, 2010), (Hedlund M, 2011), 
(Zhan R, 2009), (Clayton A T. A., 2005), (Chen T, 2011), (Miyazaki Y, 
1996).  
Moreover, p53 activation is also caused by “ribosomal stress”, a condition 
caused by aberrant ribosome biogenesis (Pestov DG, 2001), (Rubbi CP, 
2003). Consequently, defects of ribosome biogenesis lead to a number of 
ribosomal diseases (Raiser DM, 2013).	  Diamond Blackfan Anemia (DBA) 
is the first human disorder discovered in this group.  
To date, there are no studies about vesicle production in ribosomal stress. 
To analyse EV production during ribosomal stress, we carried out the 
following objectives: 
1. We investigated EV miRNAs composition in CD34+ cells after 
induction of ribosomal stress due to silencing of RPS19 (DBA cell 
model) because miRNAs are the EV principal component (Valadi H, 
2007), (Lässer C, 2013) and the alteration in miRNA profile reflects 
the cell host condition (Théry C Z. L., 2002), (Mathivanan S J. H., 
2010)   
2. We evaluated EVs in blood from patients with DBA to better 
understand the pathogenesis of DBA and to develop a diagnostic 
test. 
 
 
3.2.1 MicroRNA signature in MVs/EXOs shed from CD34+ cells down- 
regulated for RPS19 (DBA cell model) 
 
This project was performed in collaboration with Prof. Yong Song Gho and 
co-workers who performed statistic analysis (Department of Life Science, 
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Pohang University of Science and Technology, Pohang, Kyungbuk, 
Republic of Korea) and with Prof. Antonia Follenzi who improved the viral 
construct (Department of Health Science, University of Eastern Piedmont 
“Amedeo Avogadro”, Novara, Italy). 
• Aim of the project 
EV content is representative of host cell and any perturbations in the 
homeostasis result in alterations of EV content (Skog J, 2008). From 2007 
when Valadi and colleagues demonstrated that EXOs released from human 
and murine mast cell lines contain miRNA molecules (Valadi H, 2007), 
many researchers focused on the investigation of miRNA release in vesicles 
(Bellingham SA, 2012), (Hunter MP, 2008), (Lässer C A. V., 2011). 
miRNA expression changes have been demonstrated in many diseases 
(Zang W, 2013), (Sayed AS, 2013). miRNAs are released by cells not only 
within EXOs (Mathivanan S L. J., 2010), but also within MVs (Ratajczak J., 
2006) and ABs (Zernecke A, 2009).  
In this project, we investigated miRNA signature in MVs and EXOs 
released in ribosomal stress. For this purpose, we used CD34+ cells silenced 
for RPS19. After miRNA extraction from MVs and EXOs the intra-vesicles 
miRNome was identified.   
 
• Experimental plan and methods 
CD34+ cells were purified from cord blood collected from healthy donors. 
Mononuclear cells were isolated by Ficoll-PaqueTM Premium (GE 
Healthcare), and then CD34+ cells were separated by immunomagnetic 
procedure (Miltenyi Biotech) and cultured in StemSpan® Serum-Free 
Expansion Medium (SFEM) (STEMCELL Technologies) in the presence of 
SCF (50ng/ml), Flt3-L (50ng/ml), TPO (20ng/ml), IL-3 (10ng/ml) and IL-6 
(10ng/ml) (all cytokines were from ImmunoTools).  
To transiently silence RPS19, CD34+ cells were transduced with 70 MOI 
(Multiplicity Of Infection) of a third generation pCCL lentivirus vector 
(Follenzi A, 2000), expressing scramble or RPS19 shRNA (Miyake K, 
2005). CD34+ cells transduced by RPS19 shRNA are indicated as CD34+C, 
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whereas, CD34+ cells transduced with the virus expressing scramble shRNA 
are called CD34+S and were used as negative control. Transduction 
efficiency was evaluated after three days by detection of GFP with a 
FACSCalibur flow cytometer (BD Biosciences). Cells were cultured four 
days after transduction and then RNA was extracted from MVs and EXOs 
shed from cells. To analyze vesicular miRNAs, a method based on filter 
isolation of vesicles has been used. This method is based on size only, thus 
vesicle characterization is less accurate than that obtained using the 
procedures reported in section 3.1 of this thesis. We used ExoMirTM PLUS 
Kit (Bioo Scientific) according to the manufacturer’s protocol. Briefly, 
using this kit, cell supernatant is passed over three syringes filters connected 
in series; the top filter (filter 1) has pore size of ~700 nm, the middle filter 
(filter 2) has a pore size of ~200 nm, and the bottom one (filter 3) has the 
smallest pore size of ~20 nm. RNAs from captured particles were extracted 
flushing filters with a RNA lysis buffer included in the kit. Only RNA 
samples extracted from filter 2 and filter 3 were used for miRNA array 
analysis. In this work, particles captured by filter 2 are within the size of 
microvesicles (MVs, with a size of 700-200 nm) whereas those ones from 
filter 3 are in the range size of exosomes (EXOs, with a size of 200-20 nm) 
(Crescitelli R, 2013). 
To evaluate RNA quality and concentration, RNA samples were analysed 
with Agilent 2100 Bioanalyzer (Agilent Technologies) following the 
manufacturer’s procedures. Then, 100 ng of RNA from MVs and EXOs 
were analysed using The Nanostring® nCounter system (Nanostring® 
Technologies). RNA was incubated in presence of miRNA specific capture 
and reporter probes. Non-hybridized probes were removed and the purified 
hybridized complexes were immobilized and aligned for data collection as 
previously reported (Geiss GK, 2008). The Nanostring® nCounter miRNA 
Expression Assay Kit allows miRNA profiling with superior specificity and 
sensitivity and with lower cost than microarrays. The nCounter Analysis 
System delivers direct, multiplexed measurement of miRNA expression, 
providing digital readouts of the relative abundance of 800 miRNAs 
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simultaneously. The system is based on target-specific probe pairs that are 
hybridized to the sample in solution.  
RNA expression was normalized by quantile normalization with MATLAB 
(version 2010a). Significant miRNA changes were selected using the 
following criteria: 
• Statistical significance – miRNA expression changes were 
identified using a p-value threshold of 0.05;  
• Fold change expression – a minimum of 1.5-fold difference in 
either direction was required. 
Fold changes (log2-ratio) were calculated also by MATLAB (version 
2010a). Quality control was performed not only by depicting the scatter 
plots of relative RNA expression, but also by performing principal 
component analysis (PCA), which is provided by MATLAB (version 
2010a). The PCA has been performed on three independent experiments. 
PCA analysis showed that miRNA expressions in MVs shed from CD34+S 
in experiment three were outliers (probably because of RNA degradation). 
This experiment was disregarded before further analysis.   
 
• Results and discussion 
We used an innovative method to obtain a miRNA signature from MVs and 
EXOs released in ribosomal stress. miRNAs that were included in 
MVs/EXOs released during ribosomal stress (CD34+C) were compared with 
those identified in their scramble control (CD34+S). As shown in figure 15, 
similar overall patterns were observed both in MVs and EXOs. Both 
comparisons showed and high correlation: ρ =0,9065 in MVs C vs MVs S 
and ρ =0,8984 in EXOs C vs EXOs S.  
Setting up the statistic significance (P-value=0.05) and the fold change (<-
0.5 or >0.5), volcano dot plot was obtained illustrating the overall pattern of 
miRNAs (Fig. 16). Specifically, in MVs C versus MVs S, three miRNA 
were up-regulated (miR-412, miR-1281, miR-1273f) and eight were down-
regulated (miR-153, miR-1248, miR-526b-5p, miR452-5p, miR-105-5p, 
miR-374a-5p, miR-148a-3p and miR-588).  
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Fig 15: Correlation between miRNA expression in MVs and EXOs shed from 
RPS19 silenced cells (C) vs scramble control (S). Each dot represents one miRNA 
with its respective mean log2 intensity in different samples. Spearman correlation 
coefficient (ρ) is indicated. 
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Fig. 16: miRNAs signature in MVs and EXOs shed from CD34+ cells silenced for 
RPS19 (MVs/EXOs C) compared with negative control (MVs/EXOs S). Probe sets 
corresponding to miRNAs from different vesicles (MVs and EXOs) and different 
conditions (C and S) are displayed on volcano plot. The miRNAs with high fold 
change (x-axis, fold-change >1,5 or fold change <-1,5) and low p-value (y-axis, 
p<0.05) are annotated and indicated in red. 
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Comparing miRNAs changed in EXOs C versus EXOs S, just one miRNA 
showed to be up-regulated (miR-643), whereas four miRNAs were down- 
regulated (miR-654-3p, miR-1276, miR-539-5p and miR-188-3p).  
Abnormally expressed miRNAs are listed in table 1 (P-value and fold 
change for each miRNA are indicated). Fold change variations are shown in 
figure 17A-B. The different pattern for MVs and EXOs reflects the different 
biological processes in EV production and in cargo loading. 
 
 
miRNAs' P(values'
Fold'changes'
C'vs'S'
MVs$up'regulated$
hsa'miR'412$ 0,0087$ 0,6$
hsa'miR'1281$ 0,0392$ 0,6$
hsa'miR'1273f$ 0,0349$ 0,8$
MVs$down'regulated$
hsa'miR'153$ 0,0423$ '0,7$
hsa'miR'1248$ 0,0453$ '0,6$
hsa'miR'526b'5p$ 0,0298$ '0,7$
hsa'miR'452'5p$ 0,0353$ '0,9$
hsa'miR'105'5p$ 0,0231$ '0,9$
hsa'miR'374a'5p$ 0,0119$ '1,0$
hsa'miR'148a'3p$ 0,0144$ '0,9$
hsa'miR'588$ 0,0153$ '0,6$
EXOs$up'regulated$
hsa'miR'643$ 0,0200$ 1,7$
EXOs$down'regulated$
hsa'miR'654'3p$ 0,0281$ '0,6$
hsa'miR'1276$ 0,0098$ '0,6$
hsa'miR'539'5p$ 0,0290$ '0,8$
hsa'miR'188'3p$ 0,0419$ '1,3$
Table'1:''Up('and'down(regulated'miRNAs'in'MVs'and'EXOs'shed'
from'cells'silenced'for'RPS19''
(MVs'C'vs'MVs'S'and'EXOs'C'vs'EXOs'S)'
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Fig. 17: Fold-change variations between miRNAs in vesicles shed from CD34+ 
silenced for RPS19 (C) versus negative control (S). A) miRNAs that vary in MVs 
and B) in EXOs. Only significant variations (P<0.05) are presented. 
 
 
Most of the altered miRNAs (miR-412, miR-1281, miR-153, miR-526b-5p, 
miR-452-5p, miR-105-5p, miR-374a-5p, miR-148a-3p, miR-643, miR-654-
3p, mir-1276, mir-539-5p and mir-188-3p) are listed in EVpedia 
(http://www.evpedia.info), the most accurate database of molecules 
enriched in EVs.  
To understand more thoroughly how these miRNAs may contribute to 
pathways activated in ribosomal stress, we examined miRNA targets as 
predicted using TargetScan 6.2. Unfortunately, not all 16 miRNAs are listed 
in this database or some of them are annotated in other species. We 
identified 752, 148 and 697 genes that were predicted to be targeted by 
miR-153, mir-588 and miR-539-5p respectively. Setting up the total context 
score+ <-0.31, no overlap among target genes from these three different 
miRNAs have been found. However, one gene was targeted both by miR-
539-5p and miR-153 i.e. BTBD7, a regulatory gene involved in embryonic 
development of mammalian salivary glands and lungs (Onodera T, 2010) 
and in hepatocellular carcinoma progression (Tao YM, 2013). 
Several altered miRNAs are related to haematopoiesis and blood cells such 
as miR-155 (Georgantas RW 3rd, 2007), miR-15b, miR-16, miR-221, miR-
185 and many others (Choong ML, 2007). A study focused on miRNA 
expression in blood cell lineages and stages of hematopoietic stem cell 
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differentiation demonstrated that miR-148a have a role in DNA methylation 
of CD34+ cells (Merkerova M, 2010). 
Many miRNAs found in our analysis are included in human cancer 
signatures. For example, miR-412 and miR-1281 are found to be involved 
in lung cancer (Gao W, 2011) and muscle-invasive bladder cancer (Pignot 
G, 2013) signature respectively. miR-452 is involved in hepatocarcinoma 
(Chiu LY, 2013) and breast cancer (van Schooneveld E, 2012), whereas 
miR-374a is up-regulated in osteosarcoma cell lines (Namløs HM, 2012) 
and in follicular lymphoma (Wang W, 2012). Furthermore, a potential 
diagnostic use was proposed for miR-1248, miR-526b-5p and miR-452 in 
asthma (Panganiban RP, 2012), pregnancy (Kotlabova K, 2011) and uveal 
melanomas (Ragusa M, 2013) respectively. 
Interestingly, two of these miRNAs are involved in cell death i.e. miR-412 
(Melamed Z, 2013) and miR-153 (Wu Z, 2013). Melamed et al 
demonstrated that tissue-specific alternative splicing regulates maturation of 
miR-412, whose targets encode a protein network involved in neuronal cell 
death processes (Melamed Z, 2013). 
miR-153 is the only one whose gene targets are predicted in three databases 
(TargetScan, MicroCosm and PicTar). miR-153 has an anti-apoptotic 
function. In breast cancers cells a decrease of miR-153 expression increased 
apoptosis and inhibited proliferation (Anaya-Ruiz M, 2013). Differently, 
other authors demonstrated that miR-153 is over-expressed in prostate 
cancer, where it induces cell cycle transition and cell proliferation. miR-153 
up-regulation promotes cell proliferation through down regulation of its 
target PTEN. Consequently to PTEN decrease, cyclin D1 is overexpressed 
and p21(Cip1) down-regulated (Wu Z, 2013). miR-153 is down-regulated in 
MVs shed from CD34+ cells after RPS19 silencing, but we do not know if it 
has the same behaviour within these cells. Thus, miR-153 levels need to be 
evaluated in these cells. If miR-153 levels are decreased also in cells, this 
miRNA may have a role in DBA by inducing apoptosis. Interestingly, 
PTEN may have an important role in ribosomal stress because of its ability 
to repress RNA polymerase I transcription and indirectly regulate rRNA 
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transcription (Zhang C, 2005). Furthermore, PTEN regulates expression of 
genes involved in apoptosis via Bcl2 and Mcl1 in glioblastoma cell line (Xu 
J, 2011). It controls FOXO1 expression in endometrial cancer cell lines 
(Myatt SS, 2010). miR-153 involvement in stretch stress (Song L, 2012) 
could support its role in other stress types such as ribosomal stress. 
In conclusion, a miRNA signature in MVs and EXOs released in ribosomal 
stress has been identified. These results need to be validated using other 
methods such as qRT-PCR. Functional analyses are also mandatory. Assays 
such as MTT, colony formation and BrdUrd incorporation may be 
performed to investigate miRNAs involved in cell proliferation. 
Investigation of miRNAs from EVs could be useful to shed light on 
molecular process involved in ribosomal stress and to understand 
pathophysiology of DBA.  
 
 
3.2.2 Diagnostic potential of extracellular vesicles – characterization 
and quantification of microparticles in patients with Diamond Blackfan 
Anemia (DBA) 
 
This project was performed in collaboration with Prof. Giorgio Bellomo and 
co-workers, (Chemical Clinical Analysis laboratory, SCDU, Azienda 
Ospedaliera Universitaria Maggiore della Carità, Novara, Italy) and with 
Prof. Ugo Ramenghi and co-workers, (Department of Pediatric and Public 
Health, University of Turin, Torino, Italy). 
 
• Aim of the project 
The finding of abnormalities in vesicles shed from cells representing a 
model for DBA prompted us to explore the diagnostic potential of erythroid 
vesicles in patients with DBA.  
DBA is a genetic disorder induced by a defect in ribosome biogenesis. It is 
characterized by a deficiency of red cell progenitors, that show a pro-
apoptotic phenotype and die in the bone marrow. One of the major factors 
3.	  Results	  and	  discussion	  	  
	   97	  
limiting DBA research has been the inability to study the patients’ erythroid 
progenitors in the bone marrow.  
Our hypothesis was that peripheral blood from DBA patients contained EVs 
derived from erythroid progenitors. A quantification and a detailed 
characterization of these EVs could be useful not only to investigate the 
pathophysiology of the disease, but also as a useful tool for diagnosis.  
It is important to note that the isolation of microvesicles derived from 
erythroid precursors has never been attempted so far. 
To test our hypothesis, EVs were collected from blood of patients with 
DBA and appropriate controls. Vesicle markers were then studied by flow 
cytometry. 
 
• Experimental plan and methods 
In this section I will refer to EVs as microparticles (MPs) because EVs 
from blood are commonly named in this way in literature. MPs 
corresponding to vesicles have a size less than 1000 nm (Simak J, 2006) 
(Freyssinet JM, 2010), (Hargett LA, 2013), (Rubin O, 2012).   
Peripheral blood samples were drawn from healthy controls (n=19), patients 
with non-DBA haematological disease (n=10) and patients with DBA (n=8). 
All patients or their parents signed and informed consent form (Department 
of Pediatric and Public Health, University of Turin, Italy). Venipuncture 
was performed using Safety-LokTM Blood Collection Set (Becton Dickinson 
Vacutainer®) and blood samples collected in sodium citrate (3.2%) tubes 
(2.7ml). MPs were isolated using differential-centrifugation steps. Blood 
was centrifuged at 2400 × g for 10 min at RT, plasma without platelets 
(about 2ml) was centrifuged at 1800 × g for 30 min at 4 degrees. 
Supernatant was transferred to ultracentrifugation tubes and MPs collected 
at 100000 × g for 1 hour at 4°C. Pellet was resuspended in 1 ml of 0.22 µm 
pore size membrane-filtered PBS 1% and kept at 4°C over night. At the last 
centrifugation steps (100000 × g) all vesicle types should be collected. 
However, MP pellet was further centrifuged after labeling with antibodies 
as described below. At that centrifugation step (1800 × g for 30 min) only 
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ABs should be collected (Crescitelli R, 2013). However, we showed that 
MPs are variably positive to phosphatydilserine (Fig. 26). This may indicate 
that the MP pellets were composed by both ABs and MVs. 
MP signals were acquired by flow cytometry using the FACSCanto II 
(Beckton Dickinson) instrument and analysed using FacsDiva software 
(Beckton Dickinson).  
Standard size micro beads (1-2 µm) were used to set the MP gate (Flow 
Cytometry Size Calibration Kit, Invitrogen) (Fig. 18). 
 
 
 
Fig: 18: Flow calibration test. Beads with two diameters (1 and 2 µm) were used to 
set the upper and lower size limit. Beads were analysed in FSC vs SSC plot (A) and 
in FSC vs number of events histogram (B). 
 
The lower limit (500 nm) was set taking into account the instrument limit 
(Freyssinet JM, 2010), (Lacroix R, 2010), the upper one (1000 nm) has been 
used to avoid analysing cell debris, platelets, MP aggregates or apoptotic 
bodies. 1 µm, in fact, is considered as the upper size limit when defining 
MPs (Gelderman MP, 2008). 
To characterize MPs from erythroid progenitors we tested MP positivity to 
the following markers: CD34, CD71 (markers of erythroid progenitors) 
(Furness SG, 2006), (Fajtova M, 2011), CD235a (glycophorin A, typical 
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marker of MPs shed by reticulocytes) (Fajtova M, 2011). Furthermore we 
tested MP populations for their positivity to phosphatidylserine (PS), a MP 
marker still under discussion (Connor DE, 2010). It has been demonstrated 
that only a limited portion of MPs in blood is PS+ (Gelderman MP, 2008), 
(Nielsen MH, 2014). To set a positive versus negative discrimination limit, 
samples were incubated also with isotype controls IgG2A/IgG1. The three 
antibodies and Annexin V (all from Beckton Dickinson) were labelled with 
different fluorochromes and incubated with sample in three different tubes: 
Tube 1: IgG2A-FITC1/IgG1-PE2 (20µl) 
Tube 2: CD71-FITC1 (10µl), CD34-PE2 (10µl), Annexin V-APC3 (2,5µl) 
Tube 3: CD71-FITC1 (10µl), CD34-PerCP4 (10µl), CD235a-PE2 (10µl), 
Annexin V-APC3 (2,5µl) 
(1Fluorescein isothiocyanate, 2Phycoerythrin, 3Allophycocyanin, 4Peridinin 
Chlorophyll Protein Complex) 
 
100 µl of MPs (resuspended in PBS) were incubated with the three different 
antibodies combinations (tube 1, tube 2, tube 3) for 15 min in dark 
conditions. Samples were washed adding 1 ml of 0.22 µm pore size 
membrane-filtered PBS 1X and centrifuged at 1800 × g for 30 min at 4 °C. 
MP labelled pellet was resuspended in 400 µl of Annexin V buffer (Beckton 
Dickinson) (diluition 1:10) and Annexin V added to tubes 2 and 3. 
The MP absolute numbers of different populations investigated were 
calculated using TruCountTM Tubes. These tubes contain a defined number 
of beads which allow to analyse MP number by the following formula: MP 
count/µl= [(MP event count)/(TruCountTM bead event count)] * [(total 
TruCountTM beads)/100 µl] *1.1      1.1 is the dilution factor 
Student t-test and Kruskal-Wallis test have been performed to compare 
means from the different groups investigated. Mean differences were 
considered statistically significant if p-value < 0.05. 
Receiver operating characteristic (ROC) curves were established to evaluate 
the diagnostic accuracy needed to differentiate healthy controls versus 
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patients with DBA and all controls versus patients with DBA. The program 
Stata V11.0. (Stata Corp. College Station, Texas, USA) was used. 
 
• Results and discussion 
MPs shed from erythroid cells were analysed in plasma from 19 healthy 
controls (12 females, 7 males; age range: 10-56), 10 patients showing a non-
DBA haematological disease and 8 patients with DBA (3 females, 5 males; 
age range: 5-42). Clinical data from these patients are reported in table 2 
and 3. Clinical characteristics and mutated RP genes in patients with DBA 
were shown in table 3A. BFU-e colony number obtained from peripheral 
blood and bone marrow of patients with DBA and performed for clinical 
assessment are reported in table 3B (Dianzani I, 1997).  The colony number 
from both peripheral blood and bone marrow was zero or very small in all 
patients with DBA analysed. 
Individuals #7 and #8, indicated with a different colour, are 
consanguineous. Patient #7 is the father of patient #8. He is in complete 
haematological remission, whereas his son, that has never required 
treatment, shows macrocytosis. 
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Table&2:&characteris/cs&of&healthy&controls&and&
pa/ents&without&DBA&
HEALTHY&CONTROLS&#& GENDER& AGE&
1" F" 24"
2" F" 25"
3" M" 33"
4" F" 32"
5" F" 26"
6" M" 35"
7" F" 26"
8" F" 26"
9" M" 26"
10" F" 56"
11" F" 25"
12" M" 26"
13" F" 24"
14" M" 10"
15" F" 32"
16" F" 24"
17" M" 24"
18" M" 26"
19" F" 25"
 PATIENTS&WITHOUT&DBA&#& CLINICAL&CHARACTERISTICS&
20" chronic"thrombocytopenia"
21" iron"deficiency"anemia"with"iron"treatment"and"normal"value"of"Hb"
22" heterozygosis""for"HbS,"normal"Hb"value"(12,2"g/dl),"age:"2"
23" iron"overload,"microcytosis""(Hb:"9g/dl)"
24" lymphadeniLs"
25" congenital"dyserythropoieLc"anemia"type"II"(Hb:"9,9"g/dl)"
26" thrombocytopenia"
27" autoimmune"lymphoproliferaLve"syndrome""
28" spherocytosis,"splenectomy,"normal"Hb"value"(Hb:"14,4"g/dl)"
29" spherocytosis,"splenectomy,"normal"Hb"value"(Hb:"17,5"g/dl)"
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The MP flow cytometry analysis has been performed using a dot plot graph. 
A representative dot plot is showed in figure 19. The analysis has been 
focused on MPs in the MP gate (500-1000 nm) (Fig. 19A). 
DBA$$
pa'ents$#$ gender$ age$ muta'on$ malforma'ons$ low$stature$
ADA$$
$(IU/ml$Hb)$ therapy$
1" M" 7" unknown" accessory"spleen" NO" 0,9" transfusions"
2" M" 24" RPL11"c.314A315delTT"
turbidity"of"the"
vitreous"body" YES" 3,2" transfusions"
3" F" 42" del."RPL5" micrognathia,"neck"carNlage"growth"" YES" 3,9" steroids"
4" M" 5" unknown" NO" NO" 1.4" transfusions"
5" F" 27" parNal"del."RPL11" YES" YES" increased" parNal"remission**"
6" F" 13" unknown" Tetralogy"of"Fallot" unknown*" transfusions"
7" M" 36" RPS24"c.64C>T"(Q22X)" heart"malformaNon" YES" 5,2" remission***"
8" M" 8" RPS24"c.64C>T(Q22X)" heart"malformaNon" 2,8" not"treated"****"
*"not"analysed"because"paNent"has"been"immediately"treated"with"transfusion"
**"macrocytosis"(Hb:"9g/dl)"
***"macrocytosis"(Hb:"11g/dl)"
****"macrocytosis"(Hb:"12g/dl)"
Table$3:$characteris'cs$of$pa'ents$with$DBA$
A)$
B)$
DBA$$
pa'ents$#$
bone$marrow$
condi'ons$
erythroid$colonies$
(BFUEe)$in#vitro#
BFUEe$colonies$
source$
BFUEe$colonies$#$in$
basal$condi'ons"
BFUEe$colonies$$
#$using$SCF$
1" erytroid"hypoplasia" reduced"growth" PB" 1" 8"
BM" 23" 26"
2" erytroid"aplasia" growth"with"SCF" PB" 0" 1"
BM" 0" 46"
3" PB" "1,"very"small"
7,"small"and"
containing"small"
amount"of"Hb"
4" erytroid"aplasia" reduced"growth" BM" 0" 0"
5" erytroid"aplasia" growth"with"SCF" BM" 0" 7"
6" erytroid"aplasia" growth"with"SCF" BM" 5,20,0*" 74,46,2*"
PB" 0,0**" 2,0**"
7" erytroid"hypoplasia" growth"with"SCF" BM" 7" 41"
PB="peripheral"blood" *"assay"has"been"performed"on"three"independent"followAups"several"years"apart"
BM="bone"marrow" *"*assay"has"been"performed"on"two"independent"followAups"several"years"apart"
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Fig: 19: MP distribution in a dot plot graph. (A) The MP gate (500-1000 nm) is 
indicated and MPs are shown in red. MP population CD71+/CD34- (in green) and 
MP population CD34+/CD71low (in light blue) are shown as observed in tube 2 (B) 
and in tube 3 (C). 
 
 
Looking at markers CD71 and CD34 in both tube 2 (Fig. 19B) and tube 3 
(Fig. 19C), two well representative MP clusters are identified: 
CD71+/CD34- in green and CD34+/CD71low in light blue. The event 
number has been calculated in the gates observed in tube 2 because of a 
better technical compensation between the two fluorochromes (FITC and 
PE) that labelled anti-CD71 and anti-CD34 antibodies.  
As shown in figure 20, the MP population CD71+/CD34- varies among 
different individuals. The graph shows representative experiments for each 
individual category: a healthy control, a patient with DBA, a patient without 
DBA, a patient with DBA in remission #7, and patient with a typical DBA 
mutation but not anemic #8 (Vlachos A B. S., 2008).  
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On the other hand, the cluster CD34+/CD71low is able to discriminate 
between patients with DBA and controls. Representative experiments are 
shown in figure 20 (a healthy control, a patient with DBA, a patient without 
DBA, a patient with DBA but in remission #7 and patient with a typical 
DBA mutation but not anemic #8). This cluster is absent in the anemic 
patient with DBA (black arrow) (Fig. 20). 
 
 
 
Fig 20: CD71+/CD34- and CD34+/CD71low populations are shown in different 
individuals: healthy control (A), patient with DBA (B), patient without DBA (C), 
patient with DBA in remission #7 (D), patient with atypical DBA #8 (E). The black 
arrow indicates the CD34+/CD71low population that is absent in the anemic patient 
with DBA, differently from the others. 
 
 
The MP number in the two populations has been calculated for all samples 
and the results are reported in table 4. 
Control #15 and #16 as well as DBA patient #1 have been analysed from 
two independent samples (a and b). The second analysis (b) has been 
performed after six months (clinical conditions were identical). Samples 
obtained in the two replicates are very similar. This shows that flow 
cytometry analyses are reproducible.   
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*a, b indicate the analysis performed on the same control or patient in two independent samples. 
**patients without DBA #23 and #24, indicated in green, show the MP CD34+/CD71low number 
similar to that of  the anemic DBA patients 
***patients with DBA #7 and #8, indicated in violet, carry a DBA mutation (RPS24 c.64C>T) but 
they do not show anemia. Their MP CD34+/CD71low number is similar to that of controls. 
 
 
The absolute number of CD71+/CD34- population is shown in table 4 and 
in figure 21A. Using a Student t-test the mean of MP CD71+/CD34- was not 
statistically significant comparing healthy controls versus patients without 
Table&4:&&MP absolute&number&calculated&in&the&gates&CD71+/CD34<&and&
CD34+/CD71low&
HEALTHY&CONTROLS&#& CD71+/CD34<& CD34+/CD71low&
1" 6,5" 0,8"
2" 10,0" 2,6"
3" 6,9" 17,8"
4" 4,6" 5,9"
5" 7,1" 1,6"
6" 9,7" 2,2"
7" 0,8" 4,9"
8" 9,6" 1,7"
9" 7,9" 5,2"
10" 4,8" 2,2"
11" 10,2" 3,8"
12" 8,7" 1,3"
13a*" 2,2" 6,2"
13b*" 5,2" 1,4"
14" 3,2" 4,2"
15a*" 134,9" 15,9"
15b*" 188,7" 2,9"
16" 9,5" 4,5"
17" 6,1" 6,4"
18" 6,1" 2,4"
19" 9,3" 5,3"
PATIENTS&WITHOUT&DBA&#& CD71+/CD34<& CD34+/CD71low&
20" 10,3" 6,5"
21" 12,2" 4,8"
22" 6,0" 1,2"
23**" 7,5" 0,6"
24**" 3,7" 0,5"
25" 6,2" 3,6"
26" 9,4" 4,1"
27" 2,8" 4,5"
28" 9,2" 1,4"
29" 7,9" 2,1"
&PATIENTS&WITH&DBA&#& CD71+/CD34<& CD34+/CD71low&
1a*" 2,3" 0,7"
1b*" 3,1" 0,4"
2" 3,2" 0,7"
3" 106,3" 0,8"
4" 25,6" 0,8"
5" 9,3" 0,4"
6" 10,0" 0,4"
7***" 3,9" 1,6"
8***" 6,7" 3,2"
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DBA and healthy controls versus patients with DBA. We conclude that this 
population is not able to distinguish patients from controls. 
On the other hand, the MP CD34+/CD71low population was less represented 
in patients with DBA as compared with healthy controls and patients 
without DBA (table 4 and Fig. 21B). Specifically, the CD34+/CD71low 
population was absent in anemic patients with DBA, but was well 
represented in controls and in patients affected by a non-DBA condition. 
The difference in MP CD34+/CD71low number between patients with DBA 
versus healthy controls is statistically significant (p<0.05 Kruskal-Wallis 
test) (Fig. 21B) as well as between patients with DBA versus all controls 
(healthy controls + patients without DBA) (p<0.05 t-test). The difference in 
MP CD34+/CD71low number between patients with DBA versus patients 
without DBA is not statistically significant, possibly due to the small 
number of analysed samples. The same result is obtained between patients 
without DBA and healthy controls. Thus, this population distinguishes DBA 
patients from controls and this last result supports the specificity of MP 
CD34+/CD71low analysis for DBA diagnosis. 
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Fig. 21: Absolute MP number in CD71+/CD34- (A) and CD34+/CD71low (B) 
populations in controls, patients without DBA and patients with DBA. (A) Patient 
#15 (a and b) in black, and patients #3 and #4, in red, are outliers. In (B) two 
patients without DBA (#23, #24), in green, show a MP CD34+/CD71low number 
similar to that of the DBA patients whereas two patients with DBA (#7, #8), in 
violet, show a MP CD34+/CD71low number similar to that controls. The mean is 
statistically significant (Kruskal-Wallis, p-value <0.05) between patients with DBA 
and healthy controls. The mean is statistically significant (Student t-test, p-value 
<0.05) between patients with DBA and all controls (healthy controls + patients 
without DBA) (data not shown). 
 
 
 
Interestingly, patients with a haematological non-DBA disease showed 
CD34+/CD71low numbers in the control range. Only patients #23 and #24 do 
not show the CD34+/CD71low population, as observed in patients with 
DBA. Patient #23 shows a still undiagnosed anemia, with severe 
microcytosis and iron overload. Patient #24 shows lymphoadenitis and 
normal erythroid parameters. We plan to repeat the analyses in this patient. 
In any case, it should be noted that these patients do not show clinical 
symptoms of DBA. 
On the other hand, two patients with DBA (patients #7 and #8) show a 
number of MP CD34+/CD71low that is similar to that of controls. They carry 
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the same RPS24 mutation, being father and son. Interestingly, they do not 
show anemia: the father shows a complete haematological remission and the 
son never displayed anemia. The son’s phenotype is named “atypical DBA” 
(Vlachos A B. S., 2008). 
Conversely, DBA patients #3 and #5, who are in partial remission, with a 
low Hb value, do not show the MP CD34+/CD71low cluster as the other 
patients with DBA. In conclusion, the low levels of MP CD34+/CD71low 
parallel Hb values in patients with mutations in DBA genes.  
Both CD34 and CD71 are erythroid progenitor markers. DBA is 
characterized by a deficiency of red cell progenitors (BFU-e/CFU-e), that 
show a pro-apoptotic phenotype and die in the bone marrow. The 
CD34+/CD71low cluster absence in blood of patients with DBA parallels the 
absence of BFU-e colonies grown from peripheral blood or bone marrow of 
these patients (table 3B). These data support our hypothesis that these 
vesicles are derived from erythroid progenitors.  
The diagnostic value of MP CD34+/CD71low analysis was evaluated using 
receiver operating characteristic (ROC) curves (Fig. 22). The ROC curve is 
a fundamental tool for diagnostic test evaluation. In a ROC curve the true 
positive rate (Sensitivity) is plotted in function of the false positive rate 
(100-Specificity) for different cut-off points of a parameter. Each point on 
the ROC curve represents a sensitivity/specificity pair corresponding to a 
particular decision threshold. The area under the ROC curve (AUC) is a 
measure of how well a parameter can distinguish between two diagnostic 
groups (diseased/normal). When the variable under study cannot distinguish 
between the two groups, i.e. where there is no difference between the two 
distributions, the area will be equal to 0.5 (the ROC curve will coincide with 
the diagonal). When there is a perfect separation of the values of the two 
groups, i.e. there is no overlapping of the distributions; the area under the 
ROC curve equals 1 (the ROC curve will reach the upper left corner of the 
plot). 
The 95% Confidence Interval is the interval in which the true (population) 
Area under the ROC curve lies with 95% confidence (Swets JA., 1988). 
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We analysed patients with DBA vs controls (healthy controls + patients 
without DBA) (AUC 0.88) (Fig. 22A), patients with DBA vs healthy 
controls (AUC 0.92) (Fig. 22B), patients with DBA vs patients without 
DBA (AUC 0.81) (Fig. 22C) and patients without DBA vs healthy controls 
(AUC 0.64) (Fig. 22 D).  
In conclusion the results show that MP CD34+/CD71low analysis is a good 
diagnostic test for DBA. 
Further analyses on patients with non-DBA anemia are needed to ascertain 
the value of this assay in the clinics. 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  
3.	  Results	  and	  discussion	  	  
	   110	  
	  	  
	  	  
Pa#ents(with(DBA(vs(healthy(controls((
+(pa#ents(without(DBA(
Accuracy:(88%(
FIG.(22(A(
Pa#ents(with(DBA(vs(healthy(controls(
Accuracy:(92%(
FIG.(22(B(
3.	  Results	  and	  discussion	  	  
	   111	  
	  	  
	  	  
Fig. 22: Receiver operating characteristic (ROC) curve evaluating the accuracy of 
the MP CD34+/CD71low analysis in A) all controls (healthy controls + patients 
without DBA) vs patients with DBA, in B) healthy controls vs patients with DBA, 
in C) patients with DBA vs patients without DBA and in D) patients without DBA 
vs healthy controls. 
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To obtain a better interpretation about CD71+/CD34- population, we focused 
on the dot plot showing CD71 and CD235a correlation (Fig. 23-24). 
 
 
 
Fig. 23: Qualitative analysis of CD71 and CD235a markers. Dot plot CD71-FITC 
vs CD34-PE (tube 2) is showed on the left panel, whereas dot plot CD71-FITC vs 
CD235a-PE (tube 3) is on the right. Populations CD71-/CD235a+ and 
CD71+/CD235a+low are shown in three representative samples. 
 
 
 
As shown in figure 23, a well distinct CD235a+ population was observed 
(CD71-/CD235a+) in many controls, many patients without DBA and one 
patient with DBA (#1). CD235a (glycophorin a) is expressed on 
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reticulocytes and erythrocytes (Fajtova M, 2011). Thus, we can conclude 
that the CD71-/CD235a+ population is shed from reticulocytes and 
erythrocytes. Moreover, in some samples this population was also positive 
for CD71 (CD71+/CD235a+ population) (Fig. 24). 
 
 
 
Fig. 24: Qualitative analysis of CD71 and CD235a markers. Dot plot CD71-FITC 
vs CD34-PE (tube 2) is showed on the left panel, whereas dot plot CD71-FITC vs 
CD235a-PE (tube 3) is on the right. Populations CD71-/CD235a+ and 
CD71+/CD235a+low are shown in four representative samples. 
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Normally, CD71 is expressed on erythroid precursors membrane and lost 
when orthocromatic erythroblast develops in to reticulocyte (Fajtova M, 
2011). The CD71+/CD235a+ population could derive from reticulocytes 
that, for different reasons, retained CD71 on their surface.  We can exclude 
that MP CD71+ are released from cells within bone marrow. In this case we 
would expect to observe a more heterogeneous MP population, expressing 
typical markers of cells in all maturation phases and not only CD71. 
In all samples (Fig. 23 and 24) a MP CD71+/CD235a+low population has 
been observed. We assume that it derives from a small amount of erythroid 
precursors released in blood circulation (Mladenovic J, 1982).   
This hypothesis is supported by the CD71+/CD34- cluster analysis in 
control #15a/b and in patients #3 and #4, where we focused on dot plots 
showing CD34 vs CD71 and CD235a vs CD71 analysed in tube 3. As 
shown in figure 25, the cluster CD71+/CD34- is so well represented in these 
samples because the population CD235a+ was variably positive to CD71 
(Fig. 25). 
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Fig. 25: Qualitative analysis of CD71+/CD34- population. Dot plot CD71-FITC vs 
CD34-PerCP (tube 3) is shown on the left panel, whereas dot plot CD71-FITC vs 
CD235a-PE (tube 3) is on the right.  
 
Analysis of different MP populations showed that flow cytometry is a useful 
system to identify MP shed from cells at different stages of erythropoiesis. 
However the flow cytometry results can be hampered by an artefact due to 
technical compensation issue. We think that marker profiling analysis need 
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to be repeated by using the same antibodies conjugated with different 
fluorochromes. 
We also focused on phosphatidylserine (PS) positivity. PS expression on 
MP surface is debated. Certain authors consider PS a marker that is not 
expressed by all types of MPs (Connor DE, 2010), (Gelderman MP, 2008). 
To verify PS expression, we re-analysed all MP populations. We compared 
all MP populations (Fig. 26A - in red) with a dot blot showing only MP PS+ 
(Fig. 26B – in blue). We observed that CD71+/CD34- cluster was PS- 
whereas CD34+/CD71low cluster was PS+ (Fig. 25 A-B). 
The same observations have been done on CD235a+ populations. The 
CD71+/CD235a+low population was PS- whereas CD71-/CD235a+ was 
PS+. Because the graphic representation was not completely exhaustive 
about CD71-/CD235a+, we quantified the MP CD71-/CD235a+ in the 
whole MP range and the in MP PS+ range in one representative sample. 
Applying the same formula used to calculate the number of MP 
CD71+/CD34- and CD34-/CD71low, we observed that 59% of MP CD71-
/CD235a+ was also PS+ in agreement with previous papers (Willekens FL, 
2008).  
In conclusion CD71-/CD235a+ population includes two subpopulations, one 
PS- and the other one PS+. We can assume that PS+ population derived 
from erythrocytes undergoing apoptosis (Lang E, 2012), (Ghashghaeinia M, 
2012) whereas MP CD235a+ PS- was shed from reticulocytes and 
erythrocytes. 
Our analysis on PS expression in MPs shed from erythroid 
progenitors/precursors supports the hypothesis that PS expression depends 
on MP origin. 
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Fig. 26: Phosphatidylserine analysis of MP populations CD71+/CD34-, 
CD34+CD71low, CD71+/CD235a+low and CD71-/CD235a+. Dot plot showing the 
MP populations in whole MP range (red) is on the left panel (A), whereas dot plot 
showing MP population in the MP PS+ range is on the right (B). A quantification 
analysis has been performed on population CD71-/CD235a+. The number of MP 
CD71-/CD235a+ PS+ is indicated (59%). The dot plots are representative of all 
samples analysed.  
 
 
 
In conclusion, since MP analysis using flow cytometry is reproducible, 
sensitive and rapid, we feel that it could be used in diagnostic routine. We 
show that it can identify MPs released from erythroid progenitors and can 
possibly distinguish DBA patients from controls. Since the DBA research 
limit is the inability to study erythroid progenitors in the bone marrow, 
analysis of MPs from erythroid progenitors in peripheral blood could also 
be useful to improve the knowledge about DBA pathophysiology. 
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Extracellular vesicles (EVs) are phospholipid membrane fragments shed 
from most cells in physiological and pathophysiological conditions (Théry 
C., 2009) (Mathivanan S J. H., 2010) (Ratajczak J., 2006) (Cocucci E, 2009) 
(Johnstone RM, 2006). They exhibit pleiotropic biological functions 
(Mathivanan S J. H., 2010). In the last years there has been a growing 
interest because of their potential use for clinical applications (van der Pol E 
B. A., 2012).  
EVs include a mixture of different vesicle types generally classified in three 
classes: apoptotic bodies (ABs), microvesicles (MVs) and exosomes 
(EXOs) (György B S. T., 2011).  
The classification is based on their size and molecular characteristics, but 
numerous similarities exist among the different EVs (György B S. T., 2011) 
(Choi DS, 2012) (Simpson RJ., 2012). Consequently, EV preparations are a 
mixture of different vesicle types. For these reasons there is a need of 
nomenclature clarification and of a standardized method able to distinguish 
EV types (Mathivanan S J. H., 2010).  
Applying previously published differential centrifugation-based protocols 
we demonstrated that the centrifugation method is useful to separate ABs, 
MVs and EXOs. Vesicles have been isolated from supernatant of three 
different cell lines (HMC-1, TF-1 and BV2) and EV types analysed looking 
at their RNA profile, morphology and surface marker expression. Our 
results show that ABs, MVs and EXOs have clearly different RNA profiles 
that allow to distinguish them focusing on rRNA. Specifically, rRNA was 
detectable in ABs from all the studied cell lines, whereas MVs contained 
little or no rRNA except for those shed from TF-1 cells. In EXOs from all 
cell lines, rRNA was absent and only small RNAs have been observed 
according with previous reports (Valadi H, 2007), (Lässer C, 2013).  
The RNA profiles for EV types were maintained also when apoptosis was 
induced.  The RNA concentration increased.  
Characterization by electron microscopy revealed a morphology compatible 
with ABs, MVs and EXOs, demonstrating that the centrifugation based 
protocol is able to separate EV subpopulations.  
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On the other hand, flow cytometry analysis using anti-CD63-coated beads 
appeared to not be a system able to distinguish each EV subpopulation. 
ABs, MVs and EXOs from both HMC-1 and TF-1 cells showed positivity 
for CD63, CD81 and CD9, except for CD9 that was absent in the TF1-
derived vesicles since TF-1 cells do not express this tetraspanin. We can 
conclude that these markers are not specific for EXOs, as previously 
thought (Mathivanan S J. H., 2010), (Théry C A. S., 2006).  
We also demonstrated that two populations of exosome-like vesicles could 
be identified. In particular, we showed that when the filtration step was 
eliminated (filter 0.22 µm pore size) two populations were collected (”EXO 
w/o filter” and “additional pellet”). Only EXO pellet was obtained using the 
filtration (”EXO w filter”).   
The EXO pellet from the sample that has been filtered (”EXO w filter”) 
contained mostly short RNAs and just small rRNA peaks, whereas the 
samples that were not filtered (“EXO w/o filter”) showed more evident 
rRNA peaks. Interestingly, the “additional pellet” contained large peaks of 
rRNA. Our result showed that using 0.22 µm filtration step, rRNA content 
is lost whereas the “additional pellet”, obtained without filtration, contains 
rRNA. The small rRNA peaks that we observed in the EXO pellet without 
filtration (“EXO w filter”) indicate a probable contamination from 
“additional pellet”. It could be interesting to investigate the effect of 
filtration using filters with different sizes because, the differences shown in 
exosome studies could be due not only to a different EXO origin but simply 
to a different filter used.   
More attention should be given to the centrifugation rotor used. “EXO w/o 
filter” and “additional pellet” cannot be separated using a swinging bucket 
rotor.  
A further purification of EXOs isolated using filter (“EXOs w filter”) and of 
the “additional pellet” was obtained loading these pellets on sucrose 
gradient. The procedure showed that “additional pellet” was composed by 
two subpopulations: one was rRNA-negative but included small RNA in 
lower fractions (1.24-1.31 g/cm3); the other was rRNA-positive and was 
4.	  Conclusions	  and	  future	  perspectives	  
	   121	  
found in the higher fractions (1.09-1.21 g/cm3). Just one EV population, 
rRNA negative and enriched with small RNA was present in “EXO w 
filter”. These results demonstrated that sucrose gradient can be useful to 
further separate and purify vesicles. 
Moreover, loading ABs, MVs and EXOs on sucrose gradient we 
demonstrated that MV pellet is composed of two subpopulations (rRNA 
positive and rRNA negative vesicles) similar to what was observed in the 
“additional pellet”. These results emphasize that the nomenclature problem 
is still an open challenge. This finding, together with the dissimilar RNA 
profiles between of 0.22 µm filtered EXOs and unfiltered EXOs, could 
explain some of the differences seen for RNA profiles in different exosomal 
studies. However, it is important to keep in mind that EV characteristics 
(size, RNA profiles, markers, etc.) could be different between EVs shed 
from different cell types and in different conditions. We suggest that every 
research group should perform a study to characterize which vesicles are 
obtained in the specific system investigated. 
After the development of a new isolation protocol to avoid a contamination 
between different subpopulations of extracellular vesicles, we applied our 
knowledge to analyse the EV role in a cellular process: ribosomal stress. 
Although EVs have been studied in many stress types and their roles 
documented, nobody studied their involvement in ribosomal stress. This is a 
cellular stress due to an abnormal ribosome biogenesis followed by 
activation of cell proliferation arrest and apoptosis (Donati G M. L., 2012). 
Defects in the ribosome biogenesis machinery induce diseases called 
ribosomopathies. Diamond Blackfan Anemia (DBA) is the first ribosomal 
disease that was shown to be due to ribosomal stress. Moreover, DBA 
research is limited by the inability to study erythroid progenitors because 
they undergo apoptosis induced by abnormal ribosome biogenesis. The EV 
study performed in this thesis has been useful to overcome this limitation 
and it represents the first EV analysis in ribosomal stress. 
We performed EV analysis in vitro using a cell model of DBA and in vivo 
using peripheral blood from patients with DBA.  
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We first analysed miRNAs included in MVs and EXOs shed during 
ribosomal stress in CD34+ cells downregulated for RPS19. We decided to 
focus our attention on miRNA EV content because they are the most studied 
EV component and their involvement in disease has been well documented 
(Corrado C, 2013). Moreover, any perturbations in the homeostasis result in 
alterations of the miRNA expression profile (Mathivanan S J. H., 2010), 
(Théry C Z. L., 2002). Analysis of miRNA content altered by ribosomal 
stress is useful to overcome the limit in DBA research due by the lack of 
erythroid progenitors and to improve the knowledge in DBA pathogenesis.  
To analyze vesicular miRNAs a methods based on filter isolation of vesicles 
has been used. This method is based on size only and filters with different 
pore sizes are used.  We captured particles with a size between 700-200 nm 
indicated as microvesicles (MVs) and particles with that ranged between 
200-20 nm indicated as exosomes (EXOs). The method used to silence 
CD34+ cells for RPS19 does not yield a sufficient amount of cells to 
perform more thorough EV separation methods, such as those detailed in the 
first part of this thesis. 
This study represents the first research focused on EVs shed from CD34+ 
cells and in condition of absence or presence of ribosomal stress. We 
compared MVs and EXOs from control cells and cells that were silenced for 
RPS19 and observed a list of miRNAs that were differently represented in 
the two experimental conditions. The first observation is that none of these 
miRNAs were in common between MVs and EXOs. This result underlines 
that different processes are used to produce EV subpopulations and to load 
their cargo.  
Many of the abnormally represented miRNAs have a role in human disease. 
Several miRNAs are involved in erythropoiesis and thus could have a role 
in DBA pathogenesis, i.e. miR-412, miR-148a and miR-153. miRNA-148 
has a role in and DNA methylation of CD34+ hematopoietic stem cells 
(Merkerova M, 2010). miR-412 and miRNA-153 are involved in cell death 
processes (Melamed Z, 2013), (Wu Z, 2013). miR-153 shows an anti-
apoptotic function in breast cancer cell cultures (Anaya-Ruiz M, 2013). In 
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particular, miR-153 accumulation leads to cyclin D overexpression and p21 
(Cip1) decrement through regulation of its target gene PTEN (Wu Z, 2013). 
The miR-153 decrement in MVs shed from CD34+ under ribosomal stress 
could explain the pro-apoptotic phenotype of cells undergoing ribosomal 
stress including DBA erythroid progenitors. Moreover, PTEN could have an 
important role in ribosomal stress because of its ability to repress RNA 
polymerase I transcription. Thus it regulates indirectly rRNA (Zhang C, 
2005). miR-153 involvement in stretch stress (Song L, 2012) could support 
its role in another cellular stress type, i.e. ribosomal stress.  
These results are just preliminary and need to be validated. Validation is 
feasible because short RNAs are stable in body fluids when surrounded by 
double phospholipid strand and the levels can be easily assessed by various 
methods such as RealTime PCR. Consequently, before performing the array 
analysis we verified the miRNA presence in our samples using RealTime 
PCR amplification (TaqMan Gene Expression Assays-Applied Biosystems). 
We analysed some common miRNAs (miR-223, miR-221 and miR-150) 
and we obtained a good amplification for all of them (data not shown).  
We will focus on the two miRNAs showing a role in cell death process 
(miR-412 and miR-153). We will investigate if their behaviour in MVs 
silenced for RPS19 in cells releasing them. In particular, miR-153 showed 
an anti-apoptotic role (Wu Z, 2013), so it is conceivable that it is down-
regulated also in cells. This behaviour could explain the pro-apoptotic 
phenotype showed by erythroid progenitors in DBA.  
To investigate its involvement in cell death induction in DBA disease, 
functional assays are mandatory. We generally use a DBA cell model in 
erythroleukemia cells (TF1) where RPS19 expression is downregulated by a 
doxycycline-inducible siRNA against the RPS19 mRNA (TF1 C), or a 
siRNA against a scramble sequence, (TF1-S) (Miyake K1, 2005).  
To validate miR-153 role in DBA we will transduce miR-153 and mir-153 
inhibitor (as control) in TF-1 C and S and we will examine the miRNA 
effect on cell proliferation. For this purpose, useful assays are MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to evaluate cell 
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viability, colony formation assay to asses cell proliferation and BrdUrd 
incorporation assay (Bromodeoxyuridine) to analyse the effect on cell cycle 
progression at G1/S transition. 
If the miR-153 role in DBA cell models is demonstrated, assays (as 
luciferase assay, specific protein level analysis and RealTime-PCR) will be 
performed to validate its predicted target genes. 
These analyses should be useful to investigate miRNA roles in pathways 
involved in ribosomal stress and in DBA pathogenesis.  
 
The EV in vivo analysis has been performed directly on EVs from erythroid 
progenitors obtained from blood of patients with DBA. In this project, we 
tried to overcome the limiting factor in DBA research represented by the 
inability to study erythroid progenitors because of their pro-apoptotic 
phenotype. Typical erythroid markers (CD34, CD71 and CD235a) a well as 
phosphatydilserine, were analysed using flow cytometry. In particular, we 
identified and quantified an EV subpopulation (CD34+/CD71low) able to 
distinguish DBA anemic patient from controls. This subpopulation is well 
expressed in controls and patients without DBA, but it is absent in patients 
with DBA.  
We observed other EV subpopulations that expressed a variable positivity to 
different makers. Their analysis has been useful to investigate the EV 
populations shed from hematopoietic cells at different developmental 
stages. In particular, a well represented EV subpopulation CD235a+ has 
been observed in controls and in one patient. CD235a+ is a marker 
expressed reticulocytes and erythrocytes. On the other hand, we assume that 
the CD71+/CD235a+low subpopulation derives from a small amount of 
erythroid progenitors released in circulation.  
We showed that flow cytometry is able to investigate EVs shed from 
erythroid cells at different developmental stages. We plan to analyse their 
content focusing on miRNA pattern. In particular we will look at miR-412 
and miR-153 if their roles in the DBA cell model are validated.  
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One of the EV research limit is the lack of methods able to separate EV 
populations positive for specific markers. For this purpose, companies are 
developing a system based on magnetic beads coated by antibodies. Thus it 
will soon be possible to isolate specifically EVs from erythroid progenitors 
to analyse their content. 
Furthermore, phosphatidylserine analysis showed that the EV 
subpopulations are variably positive for this marker. We conclude that 
phosphatidylserine positivity depends on EV origin and not from a release 
system common for all cell types. Our conclusion is in agreement with 
previous reports (Connor DE, 2010) (György B S. T., 2011).  
We demonstrated that the four markers analyzed, are able to identify EVs 
from erythroid progenitors. We would like to continue this work and 
investigate peripheral blood cells. The limiting factor is the low numbers of 
these cells. 
MPs analysis using flow cytometry resulted to be reproducible, sensitive 
and rapid and we consider this method suitable for routine testing.  
DBA diagnosis is not easy and depends on exclusion of the other bone 
marrow failure syndromes, eADA activity determination and sequencing of 
responsible genes. The finding of a low number of erythroid progenitors 
(i.e. BFU-e and CFU-e) in bone marrow samples is another useful method. 
This procedure requires two working weeks, MP subpopulation 
investigation, on the other hand, is done using peripheral blood, requires 
two working days and can be done on transfused patients.
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